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1. INTRODUCTION 
Many European nations have instituted publicly reimbursed breast cancer screening 
programs.  Internationally, private opportunistic screening is also available in numerous 
countries.  Opportunistic screening is screening "offered outside an organized screening 
program" (Canadian Cancer Society 2009).  Previous and ongoing studies have evaluated 
participation and re-uptake rates in screening and the variables that influence these rates.  
Worldwide, many studies have also focused on socioeconomic predictors of breast cancer 
screening and their effect on the stage at diagnosis (Rosenberg et al. 2005).  Fewer studies, 
however, have explored the concept of social capital in relation to screening.  If social capital 
has a significant effect on screening rates and participation, this can prove useful for policy 
and programming decisions.  Norges Forskningsråd (2005) has identified social capital as a 
potentially important factor for policymaking and problem solving efforts. 
 
The intent of this paper is to examine social capital in screening programs in general and in 
breast cancer screening programs in Norway in particular. A questionnaire distributed in 
coordination with the Norwegian Foreningen for Brystkreftopererte was used to identify 
variables that affect mammography uptake, screening, and participation as well as the 
variables that influence the use of opportunistic screening and rehabilitation.  The 
questionnaire was distributed to 3000 Foreningen for Brystkreftopererte members aged 40 to 
69 who have been diagnosed with breast cancer.  To define relevant variables, the 
questionnaire requested information about several topics, including demographic information, 
public and private screening, treatment, rehabilitation, breast reconstruction, use of follow-up 
services, social capital, health status, education, employment, and knowledge and opinions 
about genetic testing for breast cancer. 
 
In Section 2 “Screening,” the paper begins by discussing screening in general and then 
explores breast cancer screening in particular in Section 3.  Breast cancer epidemiology, 
staging and types, treatment, and rehabilitation issues are then discussed in Section 4.  
Afterwards, Section 5 of the paper addresses the concept of social capital in general terms and 
then in regard to screening and breast cancer screening.  In Section 6 social inequality is 
briefly discussed.  Section 7 “Data” provides an overview of the questionnaire responses 
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while Section 8 addresses the methods used in this study.  Section 9 addresses the results and 
analysis, and conclusions are discussed in Section 10. 
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2. SCREENING:  DEFINITION, PURPOSE, TERMS, 
AND IMPORTANT CONSIDERATIONS 
Screening may be defined as "'the systematic application of a test or inquiry, to identify 
individuals at sufficient risk of a specific disorder to warrant further investigation or direct 
preventive action, among persons who have not sought medical attention on account of 
symptoms of that disorder'” (Jepson et al. 2000, p. vii).  The goal of screening is to detect 
disease in the earliest stages in individuals who are at particular risk for the disease.  Routine 
screening is intended to detect illnesses for which there may be no symptoms or apparent 
evidence of disease.  After several years, properly implemented screening programs are 
expected to evidence a decrease in mortality (Hofvind, Geller, et al. 2007).  According to 
Miller (1985), screening programs should exhibit several characteristics, including having 
screening tests that possess appropriate sensitivity, specificity, and validity.  There are 
numerous terms and concepts that are relevant when designing or evaluating screening tests 
and screening programs.  A true-positive test result is a positive test result for someone who 
actually has the disease being tested.  A true-negative test result is a "normal or negative" test 
result for someone who does not have the disease being tested. A false-positive result is a 
positive or "abnormal" result for someone who does not have the disease while a false-
negative test result is a normal or negative result for someone who has the disease (Yarbro, 
Goodman, & Frogge 2005).  Sensitivity describes the "ability" of a test to identify people with 
disease. Low sensitivity will result in many false-negative test results, which will therefore 
lower the detection rate for cancers; if there is low sensitivity, there will be many people 
whose cancers remain undetected in the screening process.  Specificity refers to the "ability" 
of a test to detect people who do not have the disease.  While low sensitivity may lead to a 
problem of false-negative test results, low specificity may cause many false-positive test 
results in individuals who do not actually have the disease (p. 117).  
 
It is also important to consider positive predictive value (PPV) and negative predictive value 
(NPV). The positive predictive value is the "proportion of positive tests that" reflect true-
positive test results (Yarbro, Goodman, & Frogge 2005, p.117).  The PPV is affected by the 
prevalence of a disease. Corner and Bailey (2001) provide the following example: "For 
example, a test with 99% sensitivity and 95% specificity would have a positive predictive 
value of 17% with a 1% prevalence, 29% with a 2% prevalence, and 51% with 5% 
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prevalence" (p. 55). The negative predictive value reflects "the proportion of negative tests 
that are" true-negative results (Yarbro, Goodman, & Frogge 2005, p.117).  Another important 
term is validity.  Validity is "the extent to which a test measurement or other device measures 
what it is intended to measure" (Anderson, Keith, Novak, & Elliot 2002, p. 1790).  This may 
be particularly relevant when constructing evaluation criteria for screening programs. 
 
According to Yarbro, Goodman, & Frogge (2005), if a screening program is to be 
implemented for a particular disease, "the disease should have a preclinical stage before 
symptoms become obvious" (p. 117).  Mammography, for example, may identify breast 
cancer in the preclinical stage.  Also, the screening test for the disease should be "acceptable 
to the individuals being screened" as well as "widely available and easily accessible" (p. 117).  
The screening program should be for an illness that is “common…and the cause of substantial 
mortality and/or morbidity” (Miller 1985, p. 10).  In addition, the “natural history” of the 
illness “should be known” to assist in the development of appropriate screening guidelines (p. 
11).   A further consideration is that an “effective” treatment exists if illness is discovered 
during the screening process (p. 12).  As previously mentioned, the screening test should also 
be acceptable to the relevant population; it should also be safe (p. 13). Safety considerations 
help to ensure that the screening test or process is not harmful to the population being 
screened or that the risk of harm is minimal compared to the expected benefits.  X-ray 
mammography, for example, has been deemed to have an acceptable level of radiation 
exposure (Corner and Bailey 2001, p. 54; Humphrey et al. 2002, p. 194).  Appropriately 
identifying the target population for a population screening program is also quite important; 
the target population should encompass those who are “known to have a high prevalence” for 
the illness (Miller 1985, p. 15).  Methods for the evaluation of the screening program should 
also be available. 
 
Holland, Stewart, & Masseria (2006) also discuss appropriate features for a screening 
program.  Some of the features mentioned are identifying the target population and the 
individuals within that population who will be screened, encouraging those eligible for 
screening to attend screening, having “adequate premises, equipment and staff,” “an 
appropriate, satisfactory method of ensuring the maintenance of the best standards of the 
test(s),” and also “adequate and appropriate facilities” for diagnosis and treatment when 
required (p. 11).  They also outline factors for the evaluation of screening tests, including 
simplicity, sensitivity, specificity, accuracy, cost, acceptability, and repeatability. 
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A report by Wilson & Jungner (1968) for the World Health Organization (WHO) also 
discusses screening criteria, including the criterion that “There should be an accepted 
treatment for patients with recognized disease.”  In a review of the criteria proposed by 
Wilson and Jungner (1968), Andermann (2008) et al. proposed a revised set of criteria.  The 
criteria are as follows: 
"• The screening programme should respond to a recognized need. 
• The objectives of screening should be defined at the outset.  
• There should be a defined target population.  
• There should be scientific evidence of screening programme effectiveness.  
• The programme should integrate education, testing, clinical services and programme 
management.  
• There should be quality assurance, with mechanisms to minimize potential risks of 
screening.  
• The programme should ensure informed choice, confidentiality and respect for autonomy.  
• The programme should promote equity and access to screening for the entire target 
population.  
• Programme evaluation should be planned from the outset.  
• The overall benefits of screening should outweigh the harm." 
 Andermann et al. (2008) 
 
There are several more terms that are relevant to cancer screening and cancer screening 
programs. The term “prevalent screening” or “prevalent screen” refers to a person’s first 
screening.  An interval cancer is a cancer found between “two consecutive screening rounds 
following a negative” screening (Vitak 1998, p. ix).   A true interval cancer is an interval 
cancer that “even retrospectively” can not be “detected” in the person’s previous screening 
session (p. xii).  The screening interval is the time between “two consecutive screening 
rounds” (Vitak 1998, p. xi).  In Norway, for example, there is a two-year screening interval 
for the public mammography screening program. 
 
Other important terms include lead time, length time bias, and overdiagnosis (Vitak 1998, p. 
ix).  Lead time is the time period between screen detection of cancer and the time it would 
have been discovered or diagnosed based on “symptoms and signs” in the absence of 
screening (p. ix).  This is depicted in Figure 1.  Length time bias refers to the concept that the 
"outcome [may] appear better in [the] screened group because more cancers with a good 
prognosis are detected" (Fletcher 2005, p. 153).  This is related to the issue of overdiagnosis.  
Overdiagnosis refers to the fact that screening may find cancers that have "a good prognosis" 
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and would not have lead to difficulties for the patient (p. 160).  It may also be defined as the 
"detection of lesions that would not have caused clinical symptoms or morbidity" (p. 237). 
 
 
No Screening   Signs or  
      Symptoms    
 
 
        Survival 
 
Screening         Positive test result 
      Survival 
 
 
Lead Time                      (Time of Diagnosis without 
Screening) 
 
Figure 1.  Lead Time [Similar to Figure 224.1 in Hoppe 1990 (p. 1023) and Figure 2 in 
Stanley 2001 (which was reprinted from Black & Welch 1997)] 
 
Compliance is also quite important in screening.  Compliance refers to "the extent to which 
patients follow medical advice" (Fletcher 2005, p.153).  In that people who follow screening 
recommendations are following medical advice, they can be said to be exhibiting compliance.  
Other important terms include participation (or uptake) and re-attendance.  Re-attendance 
may also be called re-uptake.  In the context of mammography screening, participation rates 
measure the percentage of women in the recommended screening age who are actually being 
screened.  In certain programs, such as the Norwegian Breast Cancer Screening Program, 
participation rates measure the percentage of women invited to be screened who attend 
screening.  Re-attendance or re-uptake refers to later screenings by those who have previously 
attended screening.  For example, if the recommendation is for breast cancer screening every 
two years from the age of 50, a woman who attends screening at age 50 is exhibiting 
compliance.  She has participated in screening.  However, if she never attends mammography 
screening again, this is a lack of re-attendance.  If she does participate again in 2 years, this is 
an example of re-attendance or re-uptake.  Compliance, participation, and re-attendance may 
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be affected by a variety of factors.  These factors will be described and explored in more 
detail in the “Existing Literature” section in Section 3 “Breast Cancer Screening.” 
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3. BREAST CANCER SCREENING 
3.1 Screening Recommendations 
Various countries and organizations have established guidelines for screening programs 
(Holland, Stewart, & Masseria 2006).  The European Union Council, for example, includes 
breast cancer screening in its list of cancer screening recommendations; it recommends 
mammography screening every two to three years for women in the age range of 50 to 69 
years (European Union Council 1999). However, this differs from recommendations in some 
countries, such as the United States, in which the recommendation is for mammography 
screening to commence at age 40 (ACS 2008).  Though there is some variation in 
recommendations by various agencies and organizations, complete breast cancer screening 
recommendations in the US for the average-risk population include monthly breast self-
examinations starting at age 20, “annual clinical breast examinations” for women aged 40 and 
over and at least every three years for women aged 20 to 49, and annual “mammography 
beginning at age 40 years” (Winchester et al. 2006, p. 272).  However, “When an abnormality 
is detected on screening examination, additional diagnostic studies may include compression 
or magnification views, ultrasonography, and magnetic resonance imaging (MRI)” 
(Winchester et al. 2006, p. 272).  
 
Internationally, there are differences in screening recommendations.  As discussed earlier, 
regular breast self-exams and physical breast examinations by a healthcare provider, such as a 
gynecologist or general practitioner (family doctor), are also recommended in some countries 
as an adjunct to other screening methods (ACS 2008; Miller 1985).  An overview of breast 
cancer screening in selected countries is provided in Table 1; the table does not include 
detailed clinical breast examination and breast self-examination recommendations for all 
countries or information about private screening options in all countries. Also, much of the 
data is based on information from a 1995 survey conducted by the International Cancer 
Screening Network (ICSN) and the resulting publication by Shapiro et al. (1998), so the 
information in Table 1 is not necessarily reflective of current policies and programming in the 
countries listed.  In a literature search, a more recent comprehensive survey of international 
breast cancer screening practices was not found. 
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Table 1. Breast Cancer Screening Worldwide (Surveillance for the Average Risk 
Population) 
Country Recommended Screening 
Ages 
Screening Type Screening Interval Funding 
Norwayc 50-69 MMY 
BSE 
2 years Public, PR* 
Swedenf 40-74 (varies by county) MMY 1.5 to 2 years Public 
United 
Kingdome 
50-70 MMY 3 years Public 
Francef 50-69 MMY 2-3 years Public 
The 
Netherlandsf 
50-69 MMY 2 years Public 
Finlandf 50-59 MMY 2 years Public 
Japanf 30 and over CBE 
BSE 
Yearly Public 
Australiad,f 50-69 (Available 40-49 and 
over 69) 
MMY 2 years Public 
USAa,b 40 and over 
 
 
20-25 
 
 
20 
MMY 
 
 
CBE 
 
BSE 
Yearly 
 
 
Yearly (40 and 
above) to every 
three years (20-39)  
Monthly 
Mostly Private, 
Public-
Medicare/Medicaid 
 
Varies 
 
 
Not Relevant 
Canadaf 50-69 (varies by province) MM 
 
CBE 
 
BSE 
1-2 years Public 
 
Public (in some 
provinces) 
PR*-Private Screening is also available. 
MMY (Mammography), BSE (Breast Self-Examination), CBE (Clinical Breast Examination) 
Sources: (ACS 2009a; Sloan-Kettering 2009b; Kreftregisteret 2009c; Australian Government Department of 
Health and Ageing 2009d; UK NHS 2009e; Shapiro et al. 1998f ) 
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3.2 Breast Cancer Screening in Norway 
The publicly-funded Breast Cancer Screening Program in Norway is described in detail by 
numerous sources (Hofvind, Geller, et al. 2007; Hofvind, Wang, & Thoresen 2003; Østerlie 
et al. 2008; Hofvind, Vacek, Skelly et al. 2008).  The program was implemented nationwide 
over a period of years; this was preceded by a pilot program (Hofvind, Sørum, & Thoresen 
2007).  The timeline for the introduction of the public mammography screening program to 
various counties is detailed in Table 2; the information is from a chart that is available at the 
Kreftregisteret website (Kreftregisteret, 2009).  In Norway, women are invited for screening 
biennially from the ages of 50 to 69.  The “invitation” includes an appointment date and time, 
a brochure about breast cancer and breast cancer screening, and a questionnaire (Østerlie et al. 
2008).  The Norwegian Breast Cancer Screening Program meets the recommended levels of 
the European Guidelines for selected process indicators (Hofvind, Geller, et al. 2007; Perry et 
al. 2006).  Private screening options are also available, and some women respond to 
advertisements for this opportunistic screening.  This may expand the age range and 
frequency at which some women are screened beyond the age range and biennial screening of 
the public mammography screening program. 
 
Table 2.  Mammography Screening Introduction In Norway (By County) 
County Time of Introduction 
Rogaland November 20, 1995 
Oslo  January 8, 1996 
Hordaland  January 15, 1996 
Akershus  February 12, 1996 
Telemark  September 13, 1999 
Agder Counties November 1, 1999 
Troms and Finnmark  May 22, 2000 
Østfold  April 17, 2001 
Nordland  May 17, 2001 
Buskerud  September 10, 2001 
Trøndelag Counties September 17, 2001 
Oppland  January 14, 2002 
Møre og Romsdal  April 14, 2002 
Sogn og Fjordane February 3, 2003 
Hedmark  August 25, 2003 
Vestfold  February 2, 2004 
Source: Kreftregisteret 2009--Based on a chart from the Kreftregisteret website 
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3.3 Mammography 
Mammography meets the guidelines and suggestions for screening programs that were 
described in Section 2 “Screening.”  Mammography may identify breast cancer in the 
preclinical stage.  According to Strax (in Miller 1985), mammography is the “most reliable 
method for imaging breast lesions” (p. 141).  Mammograms allow the detection of breast 
cancers that may not be discovered in physical examinations.  It “is used to detect 
abnormalities and classify them as benign or malignant”; if the result is not clear or shows 
possible signs of disease, other testing and procedures, such as “supplementary views, 
ultrasound, magnification mammography, MRI, computer tomography, and nuclear medicine 
technique[s]” may be used (Alto et al. in Suri & Rangayyan 2006, p. 110).  According to the 
American Cancer Society (ACS), most breast lumps are benign.  Suspicious mammography 
results may be followed by additional mammograms, ultrasound, MRI, or biopsies.  Biopsy 
may also be used “if these methods do not lead to a definite diagnosis but indicate a high 
suspicion for malignancy, and conformation of malignancy is required” (Alto et al. in Suri & 
Rangayyan 2006, p. 110). A biopsy may be a fine needle aspiration biopsy (FNAB) or a core 
needle biopsy (CNB) (Hofvind, Geller et al. 2007; Vimpeli et al. 2008). FNAB is “a quick, 
inexpensive technique to assist in several areas of breast care management” (Fine in 
Winchester et al. 2006, p. 185).  It can help differentiate “benign from malignant solid breast 
masses” (Fine in Winchester et al. 2006, p. 185).   
 
Numerous randomized controlled trials and demonstration projects have demonstrated the 
efficacy of mammography for the detection of breast cancer lesions (Greenwald et al. in 
Miller 1985, p. 30; Miller 1985, p. 330-336).  There are, of course, instances in which false 
positives and false negatives occur; this may be due to reader error or inexperience or due to 
structural features that can not be adequately distinguished from breast cancer via 
mammography. An article by Hofvind, Thoresen, and Tretli (2004) estimated a false-positive 
recall rate using data from three mammography screening rounds in selected counties in 
Norway (p. 1501).  The results of 83,416 women aged 50 to 51 who had been screened in all 
3 rounds were used in the estimation.  Hofvind, Thoresen, and Tretli (2004) found a 
"cumulative risk of 20.8% for a false-positive recall during a screening period of 2 decades" 
(p. 1501).  The authors emphasized that "it is important to communicate the existence and 
extent of this risk to the target group" but "the cumulative risk seemed to be acceptable in the 
Norwegian Breast Cancer Screening Program" (p. 1501).  The Norwegian Breast Cancer 
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Screening Program utilizes independent double-reading of mammograms to help reduce the 
risk of false-positives and false-negatives. Also, when a woman has been screened previously, 
comparison to previous or baseline mammograms can be useful. As Hofvind, Thoresen, and 
Tretli (2004) noted, “a previous screening mammogram decreases the false-positive recall 
rate” (p. 1506). 
 
The occurrence of false-positives and false-negatives also relates to the strengths and 
limitations of mammography screening.  According to Guo, Suri, and Sivaramakrishna (in 
Suri and Rangayyan 2006), mammography screening has a sensitivity of around 70% and a 
positive predictive value of 30% and in clinical trials has also evidenced a 25% to 30% breast 
cancer mortality reduction in women aged 50 to 70 (p. 430). They caution that mammography 
has “limited specificity and sensitivity” and misses approximately 10% of cancers, “especially 
those in dense breasts” (p. 430).  They also mention that about two-thirds of those cancers are 
“detected retrospectively by radiologists” (p. 430).  Also, approximately two-thirds “of 
lesions sent to biopsy turn out to be benign” (p. 430).  The authors state that these issues have 
lead to “the investigation of alternative imaging modalities such as ultrasound, MRI, 
computer tomography (CT), and PET (positron emission tomography), etc. for the detection 
and diagnosis of breast cancer” (Guo, Suri, and Sivaramakrishna in  Suri and Rangayyan 
2006, p. 430).   
 
Randomized controlled trials have also shown that early detection of breast cancer can 
improve health outcomes (Hofvind, Sørum, & Thoresen 2007).  As mentioned previously, the 
most common method for breast cancer screening worldwide is mammography. According to 
Hagen (2007), the “triple diagnostic model” of “mammography, clinical examination and fine 
needle aspiration and/or core biopsy” has become the “gold standard for investigation of 
breast tumors.  Hagen reports a “diagnostic accuracy” of greater than 99% when the three 
methods are combined (Hermansen et al. 1987 as cited in Hagen 2007).  Mammography “has 
shown clear evidence of mortality reduction” (Kopans in Winchester et al. 2006, p. 116).  
According to Chen, Wardley, and Skarin (2007), “the widespread use of routine 
mammography has led to increased detection of early primary lesions, a factor that has 
contributed to a significant decrease in mortality” (Chen, Wardley, and Skarin 2007, p. 23).  
The Health Insurance Plan study and the Swedish Two-County trial “had sufficient numbers 
to show statistically significant mortality reduction of 20 to 30% for women invited to be 
screened” (Kopans in Winchester et al. 2006, p. 116).  Studies have demonstrated that 
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“Screening mammography reduces breast cancer mortality in women older than 50 years of 
age” (Arun and Kuerer in Winchester et al. 2006, p. 97).  Also, double reading of 
mammograms “has been shown to increase the number of cancers detected” (Kopans in 
Winchester et al., p. 117). 
 
There is some question about appropriate screening ages and appropriate screening intervals.  
Sener and Smith (2006) note that “...there were higher incidences of interval cancers in 
younger than older women and in women with increased versus decreased mammographic 
density….[This has] led to the conclusion that, while screening at a 1-year interval is likely 
more beneficial than longer intervals for all women, there clearly is more benefit to annual 
screening in younger than older women” (Sener and Smith in Winchester et al. 2006, p. 113).  
A Kunnskapssenteret report (Bjørndal and Forsetlund 2007) found that women in their 40s 
who participate in a ten-year screening program have a bit lower risk of dying of breast cancer 
compared to women who do not engage in such a program. 
 
Mammography remains an evolving technology.  Digital mammography in which the image 
is “recorded, viewed by the doctor, and stored” digitally is “under development” and is being 
used in many countries, including Norway (Suri and Rangayyan 2006, p. 432).  Initial studies 
and results suggest that “the digital mammogram is at least as accurate as the x-ray 
mammogram” while “Full-field digital mammography (FFDM) offers a field of view large 
enough to image the entire breast…” (Suri and Rangayyan 2006, p. 433 & p.432).   According 
to Sarvazyan, Egorov, Son, and Kaufman (2008), "the overall diagnostic accuracy in a large-
scaled[sic] clinical study was found of[sic] 0.78 ± 0.02 for digital mammography and of[sic] 
0.74 ± 0.02 for film mammography" (p. 91); they concluded, however, that this improvement 
was not significant. Though results of this and other studies have varied, the indication based 
on the current literature is that digital mammography may improve the detection capabilities 
of mammography. 
 
It should be noted that the efficacy of mammography and other screening techniques in 
detecting breast cancers is also affected by the type of equipment used (ex. analog versus 
digital) and by the experience of the examiner (Hofvind, Geller, Vacek et al. 2007; Hofvind, 
Vacek, Skelly, et al. 2008).  Imaging and diagnostic technologies continue to evolve.  Some 
women have observed that the mammography process is painful (Hofvind, Wang, & 
Thoresen 2003).  Newer technologies may help eliminate this potential barrier to screening.   
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3.4 Magnetic Resonance Imaging (MRI) and Computed 
tomography (CT) 
Mammography is the most commonly used method for breast cancer screening in the general 
population.  However, other methods may also be used alone or in conjunction with 
mammography, particularly for women who may be at higher risk or who may not be good 
candidates for mammography. As previously mentioned, other methods for breast cancer 
screening may include MRI in conjunction with mammography for women at higher risk 
(ACS 2008).  Different types of breast MRI, such as contrast-enhanced breast MRI, are 
available (Wu and Markey in Suri and Rangayyan 2006, p. 741).  An overview of MRI is 
provided by Suri and Rangayyan (2006): 
“MRI uses magnetization and radiowaves instead of x rays to produce very 
detailed, cross-sectional images.  The most useful MRI examinations for breast 
imaging use a contrast material that is injected into a small vein in the arm 
before or during the examination…Breast MRI is effective for all classes of 
women, has the ability to image dense breasts, and can give dynamic 
information about angiogenesis.  Although MRI can detect some conditions 
not seen on the mammogram, it is less accurate than a routine mammogram in 
determining which of the abnormal areas are cancer and which are not” (Suri 
and Rangayyan 2006, p 430-431).  
 
According to Schnall (2006), “In 1989…(it was) demonstrated that MRI was capable of 
imaging mammography occult breast cancers”(Schnall in Winchester et al. 2006, p. 162).  
However, studies of breast MRI have reported varying sensitivity and specificity (p.166-168).  
According to Hylton (2005), “Because of its high sensitivity and effectiveness in dense breast 
tissue, MRI can be a valuable addition to the diagnostic work up of a patient with a breast 
abnormality or biopsy-proven cancer.  The major limitation of breast MRI is the low-to-
moderate specificity, which in combination with high sensitivity can lead to unnecessary 
biopsy, patient anxiety, and cost” (Hylton in Morris and Liberman, 2005, p. 7).  Currently, 
studies indicate that MRI should not be used for “total population screening” but that it may 
be more “feasible” for higher risk individuals (Schnall in Winchester et al. 2006, p. 173).  
According to Schnall, “MRI should not be used as a screening test on its own, but in 
combination with mammography” (Schnall in Winchester et al. 2006, p. 173). 
 
However, current evidence has demonstrated “contrast-enhanced MRI to be effective for early 
detection of cancer in high-risk women, and superior to mammography for identifying and 
demonstrating the extent of diffuse and multifocal breast cancer” (Hylton in Morris and 
Liberman, 2005, p. 7).  In fact, “The sensitivity of MRI to breast carcinoma, particularly in 
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dense breast tissue, has led to the emerging role of MRI in breast cancer screening for women 
identified to be at high risk” (Hylton in Morris and Liberman, 2005, p. 7).   Also, “The high 
staging accuracy of breast MRI has led to its use for assessing tumor response to neoadjuvant 
chemotherapy” (Hylton in Morris and Liberman, 2005, p. 7).  Breast MRI has “a high 
sensitivity and a moderate specificity in detecting breast cancer” and  “…it has been shown 
that standard mammography misses 10 to 30% of cancers that are visible using breast MR” 
(Meinel and Reinhardt in Suri and Rangayyan  2006, p. 792). This agrees with the figures 
reported by Wu and Markey (2006).  According to Wu and Markey (2006), 10% to 30% of 
“breast cancers are not detected on mammography and the positive predictive value of 
mammography is less than 35%.” (Wu and Markey in Suri and Rangayyan  2006, p. 740).  
Therefore, it is helpful to use other imaging techniques in addition to mammography.    
 
CT scanning is sometimes used, but “The use of CT has been limited as a diagnostic tool of 
breast abnormalities because of radiation hazard and image quality”; therefore, “CT is 
preferred in systemic staging of breast cancer patients” (Suri and Rangayyan 2006, p. 431). 
3.5 Ultrasound (US) 
As previously mentioned, mammography is the most common method for breast cancer 
screening and is considered the “gold standard” for breast cancer screening (Peart, 2005, p.  
xi). However, ultrasound may also be used to investigate breast cancer and other 
abnormalities. Ultrasonography may be particularly useful in combination with 
mammography in certain cases, such as the presence of dense breast tissue, investigation of a 
palpable lump, or for “surveillance of high-risk women” (Hagen 2007, p. 9).  According to 
Suri and Rangayyan (2006), “The most widely used adjunctive modality for breast imaging is 
ultrasound…Ultrasound is particularly valuable for…examining younger women with dense 
breasts” (Suri and Rangayyan 2006, p. 740).  Also, “Ultrasound has become a valuable tool to 
use with mammograms because it is widely available and less expensive than other options.  
Breast ultrasound is used to target a specific area of concern found by the mammogram.  It is 
a widely accepted adjunct to mammography in patients with palpable masses or symptomatic 
breast disease.  It is well established that breast ultrasound can distinguish solid from cystic 
masses with an accuracy approaching 100%, and can detect lesions that are not 
mammographically visible’”(Suri and Rangayyan 2006, p. 430-431; Fornage in Winchester et 
al. 2006, p. 137).  However, it does have limitations.  According to Fornage (in Winchester et 
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al. 2006), “As a rule, sonography cannot depict isolated microcalcifications that would 
indicate the presence of an early intraductal carcinoma; these remain the domain of 
mammography” (p. 137).   
 
It does, however, have positive features.  Fornage states that  “…with the use of state-of the-
art high-resolution ultrasound transducers, masses –cystic or solid, large or small—are 
reliably identified, and ultrasound can now play a significant role in the diagnosis and 
management of breast masses, in general, and of breast cancer, in particular” (Fornage in 
Winchester et al. 2006, p. 137). It is, of course, important that the examiner be experienced 
and properly trained.  Also, Fornage explains that “The concordance between sonographic 
and mammographic findings must be a priority for the sonologist” (p 139). Though 
ultrasound is not recommended for use without other screening methods, it does have marked 
ability to detect cancers.  Fornage even mentions that “Carcinomas, even those less than 1 cm 
in diameter, are routinely identified on US with the use of state-of-the-art sonographic 
equipment” (p. 139).   
 
Ultrasound may also be useful in staging breast cancer (Fornage in Winchester et al. 2006, p. 
147).  In addition, ultrasound can be used in ultrasound-guided fine needle aspiration biopsy 
(FNAB) of “lymph node-bearing areas” (p. 159).  Ultrasound “differentiates cystic from solid 
masses…[and] also aids in discriminating between benign and malignant solid masses” (p. 
159).  Ultrasound “can detect nonpalpable carcinomas missed by mammography…[but] it 
cannot replace mammography for routine cancer screening as it cannot demonstrate 
microcalcifications and its success is highly operator dependent.” (p. 159).  However, as 
previously mentioned, ultrasound may be useful in examinations for particular categories of 
women.  “Dense breasts…may represent a real challenge” during detection by mammography 
(Tot in Suri and Rangayyan, p. 19).  Therefore, MRI or ultrasound “are often needed for 
tumor detection” (Tot in Suri & Rangayyan 2006, p. 19-20). 
3.6 Advances in Technology 
Newer technologies are being evaluated to increase the efficacy of screening.  According to 
Suri et al. (2006), computer-aided detection (CAD) is being evaluated for use with a variety 
of breast screening and diagnosis tools, including x-ray mammography, MRI, breast 
ultrasound, and PET (Suri et al., p. 903-943).   Computer-aided detection (CAD), “automated 
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screening systems that localize suspicious regions in an image for a radiologist to consider,” 
are being evaluated to “improve sensitivity,” “such as to detect subtle lesions in 
mammography that might otherwise be missed by the radiologist” (Lo et al. in Suri and 
Rangayyan 2006, p. 872).   
3.7 Existing Literature on Breast Cancer Screening 
Attendance at breast cancer screening may be affected by a variety of factors.  As Miller 
(1985) notes, various cultural factors may decrease a woman’s likelihood of attending breast 
cancer screening.  Inappropriate understanding of risk as well as economic factors in some 
countries may have an impact on screening rates (Miller 1985).  Attendance rates for 
screening in Norway are relatively high with a 77% attendance rate for all screening rounds 
and a 76% attendance rate for the last completed round of screening (Kreftregisteret 2009).  
Studies in Norway have examined factors affecting breast cancer screening and re-attendance.  
Trust, gratitude, and convenience were considered “more important factors” than “benefits, 
harms, and risks” when women in the population studied decided whether or not to attend 
screening (Østerlie et al. 2008).  Glaeser et al. (2000) mention trust and trustworthiness as 
"two key components of social capital" (p. 811).  It should also be noted that some women 
perceived their invitation to screen with the included appointment date and time as a foregone 
conclusion; it was already decided because they had an appointment time.  The effect of the 
pre-scheduled appointment may be described as a “triggering effect” (Østerlie et al. 2008, p. 
4).  Study results also indicated that the “opt-out” nature of the Norwegian Breast Cancer 
Screening Program may overcome some barriers to screening, such as procrastination and the 
“threshold mile,” while also potentially impairing a patient’s ethical right to informed choice.  
The study also notes that women who attend the regular screening program only pay a small 
fee while those who choose opportunistic screening assume the financial costs of attendance 
(Østerlie et al. 2008).  Previous screening results and “experienced pain” were “related” to re-
attendance; however, experienced pain was not a “significant predictor of re-attendance” 
(Hofvind, Wang, & Thoresen 2003).  In the model used, intention to re-attend screening was 
the only variable that was found significant upon multiple logistic regression (Hofvind, 
Wang, & Thoresen 2003).   
 
In studies, socioeconomic status has been shown to have an impact on screening patterns.  In 
Taiwan, Lin (2008) found that participation in breast and cervical cancer screening was 
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related to age, marital status, income level, education, and health status. Lower 
socioeconomic status was related to not attending screening even when screening was free of 
charge.  Healthy behaviors, such as exercising, also appeared to have "a positive effect on the 
uptake of screening" (Lin 2008). A study of screening in Spain found that the likelihood of 
participating in opportunistic mammography screening was positively related to age, 
educational level, and having voluntary private health insurance.  Canada has a universal 
healthcare system.  Nevertheless, in an older study, Katz and Hofer (1994) demonstrated that 
screening for breast and cervical cancer in Canada was affected by income (Katz and Hofer 
1994).  Also, college graduates had a higher rate of screening than those with "less than a 
high school degree" (p. 530). 
 
In a study of the Dutch national breast cancer screening program, Lechner, de Vries, and 
Offermans (1997) found that "past breast cancer screening participation was strongly 
associated with positive determinants toward future screening participation, with the positive 
intention to participate in the next screening, and with the actual repeated participation in the 
second screening" (p. 473).  In a health technology assessment, Jepson et al. (2000) 
performed a systematic review to identify variables that affect screening participation.  They 
also tried to determine the "effectiveness of methods used to increase uptake" (p. vii).  Most 
of the studies used in the review were from Canada or the United States.  In their systematic 
review, Jepson et al. (2000) found that the following variables have a positive effect on 
participation in mammography screening: previous participation in mammography screening, 
“intention to attend,” having health insurance, or “receiv[ing] a recommendation to attend by 
their general practitioner” (p. viii).  Age was also an important factor.  The following methods 
were found to increase participation rates:  “invitation appointments, letters (less effective for 
mammography) and telephone calls; telephone counselling; and removal of financial barriers 
(e.g. transport and postage costs)” (p. viii).  The authors also mention that the following 
interventions may be effective:  “educational home visits; opportunistic screening; 
multicomponent community interventions; simpler procedures; combination of different 
components aimed at individuals; reminders for non-attenders (for mammography only); and 
invitation follow-up prompts” (p. viii).  Though their conclusions do not translate directly 
into the Norwegian setting, Doescher and Jackson (2008) found that women living in rural 
areas in the US were less likely to attend mammography screening than women living in more 
urban areas (p. 3).  They suggested that differences may be in part explained by "greater 
distances to medical facilities and less accessibility of services" (p. 3). 
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The work of Grossman (Grossman 1999; Grossman in Culyer and Newhouse 2000) is also 
relevant to discussions of healthcare and screening.  Grossman describes and elaborates on a 
human capital model.  In this model he “views health as a durable capital stock that yields an 
output of healthy time” (Grossman in Culyer and Newhouse 2000, p. 348).   He sets the 
parameters that “Individuals inherit an initial amount of this stock that depreciates with age 
and can be increased by investment” (p. 348).   There are factors and variables that may 
influence human capital.  He states that “I focus on education or years of formal schooling 
completed as the most important determinant of the stock of human capital” (Grossman in 
Culyer and Newhouse 2000, p. 373).  According to McGuire, Henderson, and Mooney 
(2005), Grossman "has tended to concentrate upon the investment demand for health" (p. 
106). In fact, Grossman postulated that education is related to an individual’s willingness to 
invest in health.  The thought is that investing in health may incur costs now but it leads to a 
reduction in costs later due to better health (Grossman in Culyer and Newhouse 2000).  In the 
context of screening, this may support the hypothesis that more years of education increases a 
person’s probability of participating in screening.  Participation in screening may be viewed 
as an investment in health. 
 
Folland (2006) also writes about variables that may impact healthcare behaviors and 
screening.  Though social capital is discussed in detail in Section 5, Folland’s treatment of 
social capital in the context of health risks will be mentioned in this section in relation to 
screening.  Folland postulates that “more extensive” relationships increase a person’s social 
capital (p. 159).  This, in turn, leads to a change in the person’s risk behaviors.  According to 
Folland (2006), “when he marries, has children, acquires friends, or experiences a more 
socially active community,” a person “chooses lower risks and thus better health” (p. 169).  In 
regard to marriage, for example, Folland suggests that within the context of the marriage or 
relationship “the decision maker…[is] motivated to preserve his social capital and thus 
himself so as to enjoy it” and concludes that “his health is thus improved by his avoiding 
health risky behaviors” (p. 160).  Extended to screening, this may lead to the hypothesis that 
increases in social capital, such as marriage, increase a person’s likelihood of participating in 
screening.   
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4. OVERVIEW OF BREAST CANCER, BREAST 
CANCER TREATMENT, AND REHABILITATION 
According to Kumle (2008), Weedon-Fekjær (2007), and Guo, Suri, and Sivaramakrishna (in 
Suri and Rangayyan 2006), breast cancer is the most common cancer among women 
worldwide with an incidence of around one million each year.  “About ten percent of women 
are confronted with breast cancer in their lives” (Guo, Suri, and Sivaramakrishna in Suri and 
Rangayyan 2006, p. 430).  In Norway, there were 2673 new cases of breast cancer in 2006, 
making breast cancer the most common cancer diagnosis for women in Norway (Larsen et al. 
2007).  According to Weedon-Fekjær (2007), "Norwegian women today have an estimated 
breast cancer lifetime risk of 10.8%, and breast cancer accounts for 3.3% of the deaths among 
Norwegian women" (p. 8).  Rovere, Warren, and Benson ( 2006) report that “Almost half a 
million women die of the disease [breast cancer] annually worldwide” (p. xi).  They also state 
that breast cancer is “predominantly a disease of post-menopausal women”; however, “almost 
one-third of cases occur in women under 50 years of age and it represents a major cause of 
death in the age group 40-50 years” (p. xi). 
 
Weedon-Fekjær (2007) reports “breast cancer incidence increases in nearly all countries”; 
Weedon-Fekjær adds that “the disease has one of the youngest median age at diagnosis of the 
most common cancers” (Weedon-Fekjær 2007, p. 7).  According to the American Cancer 
Society (ACS), the five year-relative survival rate for breast cancer ranges from 100% for 
cancers at Stage 0 or 1 at diagnosis to 86% for Stage II and reduces to 20% for Stage IV 
breast cancers (“Detailed Guide: Breast Cancer,” ACS 2008).  Early detection is therefore 
vitally important.   
4.1 Risk Factors and Breast Cancer Symptoms 
According to Humphrey et al. (2002), over half of breast cancers "occur in women without 
known major predictors" (p. 181).  However, identified risk factors for breast cancer include 
gender, age, and gene mutations.  Less than one percent of breast cancers “occur in men” 
(Anderson, Keith, Novak, & Elliot 2002, p. 237).  Women above the age of 55 have the 
highest incidence of invasive breast cancers.  Five to ten percent of breast cancers may be 
attributed to mutations in the BRCA1 (breast cancer 1), BRCA2 (breast cancer 2), or other 
genes (Ford et al. 1998, Easton 1999, & Peto et al. 1999 as cited in Hagen 2007).  BRCA1, 
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BRCA2, CHEK2, ATM, TP53, and PTEN “confer increased susceptibility to breast cancer” 
(Walker and Eeles in Isaacs & Rebbeck 2008).  “Inherited alterations in the genes called 
BRCA1 and BRCA2 are involved in many cases of hereditary breast and ovarian cancer” 
(NCI, 2002).  BRCA1 and BRCA2 “encode a tumor suppressor gene in which mutations can 
lead to breast and ovarian cancer (Miki et al. 1994 & Wooster et al. 1994 as cited in Hagen 
2007, p. 8).  “A healthy BRCA1 gene produces a protein that protects against unwanted cell 
growth…When the gene is defective, it produces a faulty protein that is unable to prevent 
proliferation of abnormal cells as they evolve into potentially deadly breast cancer” 
(Anderson, Keith, Novak, & Elliot 2002, p. 236).  “Women with mutations in these genes 
(BRCA-1 and BRCA-2) have an approximate 50 to 80% lifetime risk of developing cancer” 
(p. 96). Risk factors may vary for those with a genetic risk for breast cancer.  “Early first 
pregnancy is not protective in BRCA1 or BRCA2 mutation carriers” (p. 96).  Almost all 
hereditary cases of breast and ovarian cancers in Norway are linked to BRCA1 and BRCA2 
genetic mutations; “approximately seventy percent of the BRCA1 mutation carriers in 
Norway have one of four founder mutations” (Moller at al. 2001 as cited in Hagen 2007, p.9). 
According to Hagen (2007), “BRCA1 mutation carriers in Norway have previously been 
offered annual mammography with optional ultrasound, and clinical breast examination 
(CBE)” (p. 60).  However, breast MRI may prove to be a better “surveillance tool” for 
“BRCA1 associated breast cancers” in terms of mortality reduction (Hagen 2007, p. 60).   
Though genetic testing for some gene mutations is available, it is not routinely recommended 
in Norway.   
 
There are also other risk factors for the development of breast cancer.  Earlier age at 
menarche (younger than 12), later age at menopause (older than 55), and long-term use of 
certain kinds of hormone replace therapy (HRT) are also thought to contribute to an increased 
risk of breast cancer (Eddy 1980; ACS 2008).  This is due to “prolonged estrogen exposure”; 
as Winchester et al. (2006) summarize, “Prolonged estrogen exposure, such as early 
menarche, late menopause, nulliparity, and late age at first pregnancy are associated with 
increased risk of breast cancer” (Winchester et al. 2006, p. 96).  Additional risk factors are a 
family history of breast cancer, a previous breast cancer diagnosis, dense breast tissue, and 
some benign breast lesions.  Hypertension may also increase the risk of breast cancer 
(Anderson, Keith, Novak, & Elliot 2002).  There are several other risk factors that have been 
identified or indicated as having the potential to increase breast cancer risk.  Some lifestyle 
factors have also been suggested as risk factors for developing breast cancer (“Detailed 
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Guide: Breast Cancer,” ACS 2008).  More detailed information on risk factors is available 
from the following sources: Winchester et al. 2006, Roses 2005, ACS 2008, and Finkel 2005. 
 
According to Anderson, Keith, Novak, and Elliot (2002), “Tumors are more common in the 
left than in the right breast and in the upper and outer quadrant than in the other quadrants” 
(Anderson, Keith, Novak, & Elliot 2002, p. 237).  Early breast cancer symptoms may be 
discovered by breast self-examination; these symptoms “include a small painless lump, thick 
or dimpled skin, or nipple retractions” (p. 237).  As the cancer advances, symptoms may 
include “nipple discharge, pain, ulceration, and enlarged axillary glands” (Anderson, Keith, 
Novak, & Elliot 2002, p. 237).  The axillary area is the area under the arm commonly referred 
to as the “armpit.”   
4.2 Staging of breast cancer 
According to Winchester and Kennedy (in Winchester et al. 2006), “The vast majority of 
breast cancers diagnosed today are early stage.  The use of routine screening mammography 
and increased breast cancer awareness are primarily responsible for the trend towards earlier 
diagnosis” (Winchester and Kennedy in Winchester et al. 2006, p. 272).  “Breast cancer is 
most effectively treated when detected at an early stage, and the survival probability of the 
patient is dependent on the tumor size at detection time.  The larger the tumor size, the larger 
the probability for the presence of metastases in vital organs.  Early detection of the tumor is 
critical for a good prognosis” (Guo, Suri, and Sivaramakrishna in  Suri and Rangayyan 2006, 
p.430).  According to Eddy (1980), breast cancer can metastasize in three major ways; these 
are by growing into surrounding tissues, entering the circulatory system and thereby gaining 
access to other organs, or by using the lymphatic system to metastasize to the lymph nodes. 
“The current most commonly used staging classification [for breast cancer] is that provided 
by the American Joint Committee on Cancer” (Nurko, Broadwater, & Edwards in Winchester 
et al. 2006, p. 302).  The International Union Against Cancer (UICC) also works with the 
TNM classification system (UICC 2009).  
 
The Tumor Node Metastasis (TNM) System is also in use for other cancers.  The following is 
a basic description of the system and does not include all the details of the system in regard to 
the staging of breast cancers.  T describes the tumor size and the extent of growth of the 
tumor. N describes the progression of the cancer to lymph nodes. M describes the metastasis 
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of the cancer to other parts of the body (ACS 2008; Nurko, Broadwater, & Edwards in 
Winchester et al. 2006, p. 302).  The letters T, N, and M are modified by letters and numbers 
that provide information about the progression of the breast cancer. "X" may be used if one of 
the three characteristics can not be evaluated.  If it can be evaluated, the T may be described 
by "is" or by a number from 0 to 4.  T0 indicates that there is "no evidence of primary tumor" 
while Tis indicates carcinoma in situ; the “is” in the designation “Tis” indicates carcinoma in 
situ.  T1 to T3 indicate the size of the tumor while a "T4" "includes inflammatory breast 
cancer" and indicates a tumor of any size that is "growing into the chest wall or skin."  N may 
be modified by the numbers 0 to 3.  N0 means that the cancer has not metastasized to 
"nearby" lymph nodes.  N1 through N3 are used to describe how many lymph nodes have 
been affected by the cancer while N3 may also indicate specified conditions, such as 
metastasis to lymph nodes below the clavicle.  M may be 0 or 1.  "M0" indicates that the 
cancer has not metastasized to distant areas while "M1" indicates it has metastasized to 
"distant organs" (ACS 2008). 
 
After the T, N, and M categories are determined, the type of cancer is classified based on 
stage grouping.  Stages range from 0 to IV.  Non-invasive cancers (Tis, N0, M0) are Stage 0; 
this includes ductal carcinoma in situ (DCIS).  In Stage I (T1, N0, M0), the tumor size is 2 cm 
or less across, and the cancer has not metastasized to the lymph nodes or other parts of the 
body.  In Stage IIA (includes T0, N1, M0 as well as T1, N1, M0 and T2, N0, M0), a variety of 
situations is possible.  However, the cancer has spread to a few lymph nodes but has not 
metastasized to "distant sites."  In Stage IIB (includes T2, N1, M0 and T3, N0, M0), the 
cancer has not metastasized to distant organs.  A tumor of at least 2 cm is present and the 
cancer has metastasized to the lymph nodes or the tumor is greater than 5 cm but has not 
"grow[n] into the chest wall or skin" or metastasized to the lymph nodes.  In Stage IIIA 
(includes T0-2, N2, M0 and T3, N1-2, M0), the cancer has not metastasized to distant organs 
but has spread to certain lymph nodes.  In Stage IIIB (includes T4, N0-2, M0), the cancer has 
"grown into the chest wall or skin" and may or may not have metastasized to the lymph 
nodes.  However, it has not metastasized to distant organs.  The ACS (2008) notes that 
inflammatory breast cancer is considered Stage IIIB if it has not metastasized to distant lymph 
nodes or sites.  If it has metastasized to distant lymph nodes or sites, it is considered Stage IV.  
In Stage IIIC (includes T0-4, N3, M0), the cancer has not metastasized to distant organs but 
has spread to certain lymph nodes.  In Stage IV (includes T0-4, N0-3, M1), the cancer has 
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metastasized to distant organs or distant lymph nodes and may or may not have affected local 
lymph nodes (ACS 2008). 
 
According to Nurko, Broadwater, and Edwards (2006), “In the absence of distant metastasis, 
axillary lymph node status is the most accurate predictor of survival” (p. 302).  Axillary 
lymph nodes are lymph nodes that are located under the arm in the armpit (or axillary) region.  
“Axillary lymph node staging for breast cancer requires a clinical and pathologic assessment 
of the presence and extent of breast cancer in the regional lymph nodes” (Nurko, Broadwater, 
& Edwards in Winchester et al. 2006, p. 302). They describe axillary lymph node staging as 
“a vital prerequisite to prescribing adjuvant hormonal therapy, cytotoxic drug, irradiation, and 
surgical therapy to achieve the therapeutic goals of local, regional, and systemic disease 
control” (p. 302).  However, there are important disadvantages and effects of the use of 
axillary dissection.  They note that “Axillary dissection for nodal staging has significant 
morbidity.  The likelihood of post-operative lymphedema correlates with the extent of 
surgery.  Lymphedema also represents the operative complication most likely to cause 
permanent disability with chronic pain and is often associated with recurrent episodes of 
cellulitis.  Other complications associated with axillary lymph node dissection include 
postoperative seromas, decreased range of shoulder motion, and thrombophlebitis” (Nurko, 
Broadwater, & Edwards in Winchester et al. 2006, p. 303).  Cellulitis is "an acute 
inflammation of the connective tissue of the skin, caused by infection with staphylococcus, 
streptococcus or other bacteria" (Medline Plus 2006).  A seroma is "a build-up of clear bodily 
fluids in a place on your body where tissue has been removed by surgery" (Breastcancer.org 
2008).  Thrombophlebitis is "swelling (inflammation) of a vein caused by a blood clot" 
(Medline Plus 2008).  These effects have long-term consequences, including quality of life 
effects, for women who undergo axillary lymph node dissection. 
4.3 Types of breast cancer 
There are numerous types of breast cancers.  This paper will not discuss every type of breast 
cancer.  However, it is important to note that both the stage and type of breast cancer are 
important in determining treatment and therefore rehabilitation options.  Some breast cancers 
may be the result of several types of cancer; the term “mixed tumors” is sometimes used to 
describe them.  According to the ACS, ductal carcinoma in situ (DCIS) or intraductal 
carcinoma is the most common non-invasive breast cancer.  In this stage, the cancer is 
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contained in the ducts of the breast and has not entered the "surrounding breast tissue" (ACS 
2008).  DCIS is considered an early-stage breast cancer and has a high cure rate (ACS 2008).  
“Ductal carcinoma in situ (DCIS) of the breast is a proliferation of malignant cells within the 
lumen of the mammary duct…DCIS is the most rapidly growing subgroup within the breast 
cancer family of diseases…[In the US], [m]ost new cases (more than 90%) are nonpalpable 
and discovered mammographically” (Silverstein, MacDonald, Mabry, and Moorthy in 
Winchester et al. 2006, p. 226).  DCIS may or may not exhibit tumor necrosis.  DCIS with 
necrosis has a greater chance of being an aggressive cancer.  This type of DCIS may be called 
comedocarcinoma.  Lobular carcinoma in situ or lobular neoplasia is a condition that is 
indicated in increasing a woman's risk of invasive breast cancer. It is not a "true cancer" but 
has been identified in some reports as a non-invasive breast cancer (ACS 2008).   
 
Invasive or infiltrating ductal carcinoma (IDC) is the most frequent breast cancer.  It 
originates in a breast duct and spreads beyond the duct into the fatty breast tissue.  It may 
metastasize throughout the body using the lymphatic and circulatory systems. According to 
the ACS (2008), infiltrating ductal carcinomas represent eighty percent of invasive breast 
cancers.  Invasive or infiltrating lobular carcinoma (ILC) begins in the lobules of the breast 
and can metastasize to other areas. Ten percent of invasive breast cancers are ILCs . In a 
mammogram, it may be harder to identify invasive lobular carcinoma than invasive ductal 
carcinoma (ACS 2008).  
 
Inflammatory breast cancer is estimated to represent 1% to 3% of breast cancers. 
Inflammatory breast cancer may initially be misdiagnosed as mastitis due to its characteristic 
symptoms.  Mastitis is "an infection of the breast tissue that causes pain, swelling and redness 
of the breast," and it "most commonly affects women who are breast-feeding" (Mayo Clinic 
2008).  The symptoms of inflammatory breast cancer are caused by “cancer cells blocking 
lymph vessels in the skin” (ACS 2008).   The skin of the breast develops a red appearance, is 
warm to the touch, and has “a thick, pitted appearance…like an orange peel” (ACS 2008).  
The breast may also become “tender” or “itchy” (ACS 2008).  A complicating factor in early 
diagnosis is that inflammatory breast cancer lacks a “defined lump,” so it may not be detected 
in screening mammograms (ACS 2008).  Inflammatory breast cancer is more likely to spread 
than IDC or ILC, and the prognosis is also poorer.  Other types of breast cancer include Paget 
disease of the nipple, mucinous (or colloid) carcinoma, tubular carcinoma, and medullary 
carcinoma (ACS 2008).  
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Breast cancers may also be classified in terms of hormone receptors.  The term “triple-
negative breast cancer” refers to breast cancers that lack estrogen and progesterone receptors 
and that also lack “an excess of HER2 protein on their surfaces.” The lack of these receptors 
and the lack of “excess” HER2 protein limit potential treatments.  Hormone therapy and 
drugs that “target” HER2 are not helpful in treating triple-negative breast cancers.  Triple-
negative breast cancers are most often invasive ductal carcinomas.  Also, this type of cancer 
is more common in younger women and is likely to metastasize faster than most other breast 
cancers (ACS 2008). 
4.4 Treatment 
According to Wardley (Chen, Wardley, and Skarin 2007), “high-quality clinical research” has 
lead to better outcomes following a breast cancer diagnosis; “all aspects of breast cancer 
treatment have improved” (p. iv).  Following diagnosis, healthcare professionals may employ 
a variety of techniques to determine the progression of the breast cancer.  Additional 
mammograms, ultrasound, MRI, CT, PET scans, biopsies, bone scans, blood work, and other 
methods may be used to help determine the extent of the disease and the appropriate 
treatment options.  Treatment methods depend on a variety of factors, including type of breast 
cancer, stage at diagnosis, age, co-morbidities, and personal preferences.  The general 
treatment options available are surgery, hormone or endocrine therapy, chemotherapy, and 
radiation (radiotherapy).  Treatment may also involve a combination of these options (ACS 
2008; Hagen 2007).  
   
If surgery is indicated, different types of procedures are available. Types of surgery include 
mastectomy, breast-conserving surgery, and axillary lymph node sampling and removal. The 
surgery may or may not involve removing the lymph nodes.  Mastectomy is “the surgical 
removal of one or both breasts” Anderson, Keith, Novak, & Elliot 2002, p. 1055).   Types of 
mastectomy include radical, modified radical, and simple mastectomy.  A radical mastectomy 
is “the surgical removal of the entire breast; pectoral muscles; axially lymph nodes; and all 
fat, fascia, and adjacent tissues” (Anderson, Keith, Novak, & Elliot 2002, 1458).  Following 
surgery, the patient may experience “edema of the arm” due to removal of the “axillary 
lymphatic structures that drain the lymph from the arm” and has a risk of “symptomatic 
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atelectasis” if breathing exercises are not used (p. 1458).  Atelectasis is “the collapse of part 
or all of a lung” (Medline Plus 2008). 
 
A modified radical mastectomy is “a surgical procedure in which a breast is completely 
removed with the underlying pectoralis minor and some of the adjacent lymph nodes.  The 
pectoralis major is not excised.  The operation is performed in treating early and well-
localized malignant neoplasms of the breast.  It appears to be as curative as the more 
extensive radical mastectomy when the tumor meets these criteria” (Anderson, Keith, Novak, 
& Elliot 2002, p. 1113).  “In a modified radical mastectomy the large muscles of the chest 
that move the arm are preserved…The patient may be fitted with a prosthesis when the 
wound is completely healed or at the time of the mastectomy” (Anderson, Keith, Novak, & 
Elliot 2002, p. 1055).  
 
Anderson, Keith, Novak, & Elliot 2002 describe a simple mastectomy as follows:   
“[the]breast is completely removed and the underlying muscles and adjacent 
lymph nodes are left intact.  The procedure may be performed to remove small 
malignant neoplasms of the breast, or it may be done as a palliative measure to 
remove an ulcerated carcinoma in advanced breast cancer.  It also may be done 
prophylactically when the patient has severe fibrocystic disease and a strong 
family history of breast cancer.  Postoperatively, the process of recovery from 
a simple mastectomy is less uncomfortable and faster than that from a radical 
or modified radical mastectomy” (Anderson, Keith, Novak, & Elliot 2002, p. 
1584).  
 
A lumpectomy is the “surgical excision of a tumor without removing large amounts of 
surrounding tissue” (Anderson, Keith, Novak, & Elliot 2002, p. 1027).  “Breast conservation 
therapy (BCT) with wide local excision (also called lumpectomy, tylectomy, or segmental 
mastectomy), followed by whole-breast irradiation, has become the more common method of 
treatment [compared to mastectomy (radical and modified)] for stage 1 and 2 breast cancer)” 
(p. 1027).  “Numerous prospective and retrospective studies have shown the equivalence of 
mastectomy and breast cancer treatment with respect to disease-specific end points and the 
superiority of breast conservation with respect to quality of life measures” (Motwani and 
Strom in Winchester et al. 2006, p. 355).   
 
 As mentioned above, more conservative breast cancer surgery, such as lumpectomy, is 
becoming more common. In the past, total mastectomy was more common.  Now, studies 
have demonstrated that total mastectomy does not significantly increase a woman’s survival 
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rate (Hofvind, Sørum, & Thoresen, 2007).  Also, Finkel (2005) reports that “A twenty-year 
follow-up of a randomized study comparing breast-conserving surgery with modified radical 
mastectomy for early breast cancer found the longer-term survival rate to be the same” (p. 
43). “Total mastectomy has been replaced by breast conserving therapy (BCT) plus radiation 
for a significant majority of all patients with stage 0-II disease (Hagen 2007, p. 12).  Also, 
SLN (Sentinel Lymph Node Biopsy) “was introduced in the 1990s.  The SLN hypothesis is 
that the tumour initially drains to one or a few of the lymph nodes, and an axillary node 
dissection can be avoided if the sentinel lymph node(s) proves to be negative.  The morbidity 
of a total axillary node dissection is well-documented, and correlates negatively with quality 
of life (Tasmuth et al. 1995 & 1996 and Hacet et al. 1999 as cited in Hagen 2007, p. 12).  
“SLN biopsy can be performed in most patients with T1-2N0 invasive cancers, DCIS [ductal 
carcinoma in situ], in addition to multicentric disease and after neoadjuvant chemotherapy” 
(Hagen 2007, p. 13).  “Sentinel node biopsy has decreased the morbidity associated with the 
traditional axillary node dissection” (Hagen 2007, p. 23-24).  Based on the current evidence, 
more conservative treatment and diagnostic methods not only appear to have no detriment on 
survival rate but may also contribute to improved quality of life for women following 
diagnosis and treatment. 
 
Hormone therapy is an option for some patients.  As Anderson, Keith, Novak, and Elliot 
(2002) note, “The presence of estrogen receptors in breast tumors is considered an indication 
for hormonal manipulation such as the administration of antiestrogens (Anderson, Keith, 
Novak, & Elliot 2002, p. 237).  “Hormone-sensitive breast cancer can be effectively treated 
with agents that reduce the stimulation of tumor cells by estrogen” (Buzdar in Winchester et 
al. 2006, p. 331).  Endocrine therapy treatment plans and strategies may vary based on 
whether the woman is postmenopausal or premenopausal (p. 332).  Hormone therapies may 
function in the following ways: “blocking the receptors [for “hormone positive breast cancer 
cells],” “lowering the hormone levels,” or by “eliminating receptors” (Finkel 2005, p. 49).  
According to Finkel (2005), about 60% of breast cancers are estrogen-receptor positive (p. 
49).  Tamoxifen (or Nolvadex), for example, is an anti-estrogen medication that is often used.  
However, side effects of tamoxifen and other hormone therapy medications may include “hot 
flashes,” “headaches, fatigue, [and nausea]” (p. 50-51).  Responses to medications and 
treatment will, of course, vary for each individual. 
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Following surgical treatment, a patient may receive adjuvant therapy to target potential cancer 
cells that survived the initial treatment process (ACS, 2008).  According to Hennessy and 
Valero (in Winchester et al. 2006), “Historically, breast cancer relapse occurred in more than 
70% of women undergoing radical breast surgery alone” (p. 312).  Adjuvant systemic 
chemotherapy “reduces the risk of recurrence and death from breast cancer” (p.312).  Rovere, 
Warren, and Benson (2006) note that “The fall in mortality from breast cancer in the face of 
rising incidence rates is testimony to the success of interventional strategies in the form of 
screening and adjuvant systemic therapies, which reduce the burden of micrometastatic foci 
and perturb the natural history of this enigmatic disease” (Rovere, Warren, & Benson, 2006, 
p. xi).  Adjuvant chemotherapy “reduces such risks…through eradication of micrometastatic 
disease, which is not detectable with conventional radiological techniques at the time of 
diagnosis.  Since the risk of having micrometastatic disease at diagnosis of breast cancer is 
dependent on the stage of disease, the absolute benefit of adjuvant systemic chemotherapy is 
related to tumor size and axillary lymph node status, in addition to other factors, such as the 
age of the patient, the tumor grade, and the hormone receptor” (p. 312). Though other 
definitions and delineations have been proposed, micrometastatic disease is a term that is 
usually used to describe “tumor deposits measuring less than 2 mm” (Quan 2004).  
Chemotherapy may be used to treat cancer, “control cancerous growth,” or to ameliorate 
symptoms; Finkel notes that it may also be used to reduce the size of a tumor prior to surgical 
intervention (p. 47).  Depending on the type of treatment, chemotherapy may have a wide 
range of side effects, including “hair loss, nausea, vomiting,” and fatigue (p. 48). 
 
According to Finkel (2005), radiation targets “a specific part of the body” while 
chemotherapy and hormones “act on the whole body” (p. 45).  Finkel notes that treatment 
considerations include “patient characteristics such as age, ethnicity, tumor size, histologic 
type, hormone receptor status, and other biomarkers (measurable parameters in tissues, cells, 
or fluids” (p. 45).  Radiation serves to “kill the cancer cells directly or shrink the size of the 
tumor with high-energy external beams” and “is most harmful to rapidly producing cancer 
cells and prevents these cells from reproducing” (p. 45).  According to Finkel (2005), in some 
situations radiation may be the “only treatment needed” (p. 45).  It may also be used to 
ameliorate breast cancer symptoms or to “slow the progression” of disease (p. 45).  Radiation 
has demonstrated the ability to decrease the risk of local recurrence as well as to improve 
survival rates and the “disease-free survival rate after a follow-up time of twenty years” (p. 
45).  Brachytherapy in which “radioactive ‘seeds’ are implanted or delivered by catheter near 
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the tumor site” is also possible for certain early-stage breast cancers; this provides a more 
“targeted and localized delivery” of radiation (p. 46).  Finkel (2005) notes the following 
potential side effects of radiation: “fatigue, skin redness, burns, and skin pain” (p. 47). 
 
Some women also participate in clinical trials testing the effectiveness of newer treatment 
regimens.  Breast cancer treatment may result in a variety of side effects and present a number 
of short-term and long-term risks.  Surgery, chemotherapy, radiation, and hormone therapy all 
have advantages and disadvantages, and women in consultation with their healthcare 
providers choose a treatment plan based on their individual situations.  Treatment may 
include a variety of components, such as both surgery and chemotherapy, depending on the 
stage and extent of disease. 
4.5 Reconstruction, Follow-up, and Rehabilitation 
Though reconstruction is not always an option, a woman may decide to undergo 
reconstructive surgery. This may be part of the initial surgery or may occur during the 
recovery process (ACS 2008).  Some patients may choose to undergo immediate 
reconstruction (Fenner & Mustoe in Winchester, etc. 2006, p. 380).  “Implantation of a 
prosthesis after mastectomy is optional and does not appear to decrease survival probability.  
Reconstructive surgery is also an option” (Anderson, Keith, Novak, & Elliot 2002, p. 237).  
According to Handel and Silverstein (2006), “As a result of the emphasis on preserving a 
normal-appearing breast, the role of the plastic surgeon in treating breast cancer patients has 
great expanded” (Handel and Silverstein in Winchester et al. 2006, p. 248).  They further add 
that “In fact, the emergence of a new discipline, where the interests of the oncologic surgeon 
and the plastic surgeon overlap, has evolved into what is now labeled ‘oncoplastic surgery.’  
This term refers to application of the principles and techniques of plastic surgery to the 
challenges of treating cancer patients…In individuals who require mastectomy, immediate 
breast reconstruction can be offered in nearly all cases” (Handel and Silverstein in Winchester 
et al. 2006, p. 248).  
 
Breast cancer has not only physical effects but psychological effects as well.  Finkel (2005) 
notes the existence of a “psycho-oncology” subspecialty (p. 162).  Follow-up and 
rehabilitation focus on rebuilding the body as well as on helping women develop tools (and 
access resources) to cope with the psychological effects.  While many women struggle with 
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physical effects, such as fatigue and lymphedema, following treatment for breast cancer, they 
may also struggle with the psychological effects of illness, body image issues, and 
considering the effect of illness on their families, marriages, careers, ability to bear children, 
and future aspirations.  For some women, there may be the added burden of financial and 
economic concerns.  The recovery process is very individual and can not be generalized.  
However, for some women, it may be important to find ways of “regaining a sense of control” 
and of dealing with the fear that the cancer may recur (Finkel 2005, p. 158-161).  Others may 
prefer to find support within their existing networks of family, friends, colleagues, and 
organizations.  A comprehensive program includes options for women to address both the 
physical and psychological effects of a breast cancer diagnosis and treatment.  Options may, 
for example, include physical therapy, water aerobics, and self-help groups where women can 
have discussions with others who are undergoing (or have undergone) similar procedures. For 
women with young children, handling a breast cancer diagnosis and treatment comes at a time 
when they also have caregiving responsibilities (Kravdal 2003).  Support groups and other 
resources may prove useful to some women.  Appropriate information about rehabilitation 
options and appropriate access to rehabilitation resources can be important in the recovery 
process. Women must also work with their healthcare team to develop an appropriate plan for 
surveillance for future recurrence. 
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5. SOCIAL CAPITAL –IN GENERAL AND IN 
REGARD TO HEALTH OUTCOMES AND 
SCREENING 
Studies, theories, and definitions of social capital have been under development for a number 
of years.  Though a variety of definitions have been posited, social capital may be defined as 
“connections among individuals – social networks and the norms of reciprocity and 
trustworthiness that arise from them” (Putnam 2000 as cited in Field 2008, p. 35).  According 
to Field (2008), “[p]eople connect through a series of networks…to the extent that these 
networks constitute a resource, they may be seen as forming a kind of capital” (p. 1).   
 
In more general terms, Field notes that “In economic thought, the term ‘capital’ originally 
meant an accumulated sum of money, which could be invested in the hope of a profitable 
return in the future” (p. 14).  He traces the development of “the concept of physical capital, 
which was introduced to describe the role of machinery and buildings in increasing the 
productivity of economic activities” (p. 14).  He notes that “in the 1960s…the idea of capital 
[was] stretched to cover people and their capacities”; according to Field, Theodore Schultz 
and later Becker “developed… the idea of human capital” (p. 14).  Human capital was 
intended as “a tool to help economists measure the value of workers’ skills”; according to 
Field (2008), Schultz and Becker believed that “labour…could be more or less 
productive…and it became more productive as a result of careful investment in, for example, 
education or healthcare” (p. 14).  Capital was mostly concerned with “strictly economic 
terms”; “their [people’s] value was measurable, their worth could be added up and compared, 
the relationship between input and outputs was a direct one, and any changes in value could 
be accounted for in terms of a common currency” (p. 14). 
 
Field mentions that some have found it problematic to discuss “membership of networks” in 
terms of “capital” (p. 3).  As Field himself notes, “Social contacts are not easily reduced to a 
simple set of common denominators” (p. 15).  However, according to Field, the use of the 
term “capital” in this context “is related to the human capital tradition of thinking” and 
“similarly points to ideas of investment, accumulation and exploitation,” such as have been 
used “in such areas as global development and anti-poverty strategies or the study of business 
innovation and technological change” (p. 4).  The concept of human capital, which as 
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mentioned previously, “originally emerged in economics during the 1960s,” “denotes the 
economic value to firms, individuals and the wider public of such attributes as skill, 
knowledge and good health” (p. 10).  As previously mentioned in the “Existing Literature” 
section of Section 3, Grossman (Grossman 1999; Grossman in Culyer and Newhouse 2000) 
has described a human capital model in which he “views health as a durable capital stock that 
yields an output of healthy time” (Grossman in Culyer and Newhouse 2000, p. 348).   He sets 
the parameters that “Individuals inherit an initial amount of this stock that depreciates with 
age and can be increased by investment” (p. 348).  Social capital is an extension of a variety 
of concepts and models about capital. 
 
The original idea of capital as “an accumulated sum of money” has now evolved into the 
modern-day concept of social capital.  Field credits James Coleman “in his influential account 
of school performance in American cities” for “develop[ing] the concept of social capital as a 
way of integrating social theory with economic theory, claiming that social capital and human 
capital are generally complimentary” (p. 10).  Field mentions that the World Bank and the 
Organisation for Economic Co-operation and Development (OECD) take a similar view; a 
European commission working paper even mentions “‘the intrinsic link between human and 
social capital in the knowledge society’” (Field, p. 10-11).  The OECD has suggested the 
existence of a “‘strong complementarity’ between human and social capital, with each 
feeding the other in mutually beneficial ways” (p. 10). 
 
Another view, however, is that social capital is “an alternative to the concept of human 
capital, emphasizing the collective where the latter sees only individuals pursing their self-
interests” (p. 11).  Field finds more credence in the latter view, suggesting that “interest in 
social capital” may “represent…an attempt to modify the traditional focus of economics on 
individual behaviour, by stressing the social basis for people’s decisions” (p. 11). 
 
Field notes that interest in social capital has increased over time and that the concept has been 
used, discussed, and researched in a variety of areas and from a variety of perspectives.  In 
particular, he mentions “a remarkable growth of interest in what might be called the micro 
level of individual behavior and experience” (p. 10).  This includes studies of “intimacy and 
trust,” which Field describes as “close to the heart of social capital” (p. 10).  Social capital 
has been evaluated in regard to several different areas.  In an examination of social capital 
effects from an economic perspective, for example, Glaeser, Laibson, and Sacerdote (2002) 
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mention that "social capital is higher among homeowners" and that it "rises in occupations 
with greater returns to social skills" (p. F437). 
Field mentions that the concept that “bonds between people also serve as central building 
blocks of the larger social edifice” is not new. In 1916, Lyda Hanifan discussed “the 
contribution of ‘goodwill, fellowship, mutual sympathy and social intercourse’ to collective 
prosperity and well-being” (Hanifan as cited in Farr 2004 as cited in Field 2008, p. 15).  Also, 
Émile Durkheim was “particularly interested in the way that people’s social ties served as the 
thread from which a wider society wove itself together”; Durkheim says that “…the members 
[of society] are united by ties which extend deeper and far beyond the short moments during 
which the exchange is made” (Durkheim 1933 as cited in Field 2008, p. 13).  This suggests 
that “social ties…contribut[e] to the wider functioning of the community” (Field 2008, p. 14).  
Field says that the “central idea of social capital is that social networks are a valuable asset” 
and that those networks “provide a basis for cohesion because they enable people to cooperate 
with one another – and not just with people they know directly – for mutual advantage” (p. 
14).   
 
Field notes that “[a]s well as being useful in its immediate context, this stock of capital can 
often be drawn on in other settings” (p. 1).  Networks can stem from formal organizations, 
such as The League of Women Voters in the US, or be more informal, such as family and 
friendship connections.  Field notes that “Modern organizations are governed by rules” and 
that therefore “Calling on trusted friends, family or acquaintances is much less stressful than 
dealing with bureaucracies, and it usually seems to work faster and often produces a better 
outcome” (p. 2-3).  Field also notes that social capital and social networks do not always 
function in a positive manner.  He mentions that “Social networks can sometimes serve to 
exclude and deny as well as include and enable” (p. 3).  According to Field, “…people may 
sometimes find that options are constrained by the nature of the resources that they can get 
hold of through their connections”; however, “At other times, they will use their networks to 
liberate them from other constraints” (p. 3).  Field posits that “At other times still, they will 
use their social capital to uphold their claims over those of others who are trying to access the 
same resources” (p. 3).   
 
Field suggests that “People’s networks should be seen…as part of the wider set of 
relationships and norms that allow people to pursue their goals, and also serve to bind society 
together” (p. 3). “Gary Fine has conceived of social movements as ‘a bundle of narratives’ 
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that commits participants to shared goals and identities” (Ericksen 2008, p. 207).  The 
evolution of breast cancer organizations and programs is an excellent example.  
“Organizations to educate women about breast cancer started in the early twentieth century 
and focused on early detection” (p. 207).  The American Cancer Society, for example, has a 
Tell a Friend program, “which has placed the burden of cancer detection on individuals and 
their social networks” (p. 209). 
 
The concept of social capital has been approached from a variety of perspectives.  According 
to Field (2008), for example, in the 1970s and 1980s, Pierre Bourdieu approached social 
capital in terms of “a concern with questions of unequal access to resources and the 
maintenance of power”; “eminent American sociologist” James Coleman, on the other hand, 
“takes as his starting point the idea of individuals acting rationally in pursuit of their own 
interests” (p. 23; p. 15).  Bourdieu also noted that it was “insufficient” “to see capital solely in 
economic terms”; “both cultural capital and social capital should be treated as assets, 
representing the product of accumulated labour” (p. 18).  Bourdieu also posited that “the 
notion of social capital was the ‘sole means’ of describing the ‘principle of the social assets’ 
which was visible where ‘different individuals obtain a very unequal return on a more or less 
equivalent capital (economic or cultural) according to the extent to which they are able to 
mobilise by proxy the capital of a group (family, old pupils of elite schools, select club, 
nobility, etc.)” (Bourdieu 1980 as cited in Field 2008, p. 19).  According to Field, Bourdieu 
felt that “social capital represented an ‘aggregate of the actual or potential resources which 
are linked to possession of a durable network’” (Bourdieu 1980 as cited in Field 2008, p. 19). 
 
In regard to “educational attainment,” Coleman demonstrated that social capital 
“could…convey real benefits to poor and marginalised communities” (Field 2008, p. 23).  He 
“concluded that communities were…a source of social capital that could offset some of the 
impact of social and economic disadvantage within the family (Coleman & Hoffer 1987 as 
cited in Field 2008, p. 26).  Field mentions that “Unlike human and physical capital, which 
are normally a private good whose ownership and returns reside with individuals, Coleman 
portrayed social capital quintessentially as a public good that is created by and may benefit 
not just those whose efforts are required to realise it, but all who are part of a structure” 
(Coleman 1988-89 as cited by Field 2008, p. 26).  Coleman suggested that “relationships are 
shown to constitute capital resources by helping to establish obligations and expectations 
between actors, building trustworthiness of the social environment, opening up channels of 
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information, and setting norms that endorse particular forms of behaviour while imposing 
sanctions on would-be free riders” (Coleman 1988-89 as cited in Field 2008, p. 27).  Coleman 
felt that social capital was “‘a capital asset for the individual’…built up of ‘social structural 
resources’”; social capital was therefore “both individual and collective” (Coleman 1994 as 
cited in Field 2008, p. 28; Field 2008, p. 28).  Coleman discussed the issue of whether or not 
social resources “could be called upon in practice” (p. 28).  He felt this depended on “‘the 
actual extent of obligations held’ and ‘the level of trustworthiness of the social environment’” 
(p. 28).  These factors were “shaped by variations in social structures, including ‘…the 
general level of trustworthiness that leads obligations to be repaid, the actual needs that 
persons have for help, the existence of other sources of aid (such as government welfare 
agencies), the degree of affluence (which reduces the amount of aid needed from others), 
cultural differences in the tendency to lead aid and ask for aid, the degree of closure of social 
networks, [and] the logistics of social contacts’” (Coleman 1994 as cited in Field 2008, p. 
28).  Field says this might suggest that there were factors, “such as…a cultural propensity to 
request and offer aid,” “favouring the development of social capital” and other factors, “such 
as affluence and welfare systems,” “tending to undermine it” (Field, p. 28).  If there are 
indeed factors that foster and cultivate the creation of social capital as well as factors that 
weaken its development, then it may be possible to positively affect screening participation 
by seeking to foster those factors or variables that contribute to the development of social 
capital.  Field also noted that “Coleman’s theoretical framework allowed for the possibility 
that some constructed forms of organization were more likely to promote social capital than 
others”; Coleman felt that churches were “particularly successful at promoting closure of 
networks” (p. 30). 
 
Various definitions of social capital have been developed and used.  Coleman “defined social 
capital as a useful resource available to an actor through his or her social relationships” (Field 
2008, p. 26).  Robert Putnam has been widely recognized for his contributions to research and 
discussion on social capital (Field 2008, p. 4). In contrast to Bourdieu and Coleman, Putnam 
has “inherited and developed the idea of association and civic activity as a basis of social 
integration and well-being” (p. 15).  Field relates Putnam’s assertion that the concept of social 
capital “was invented at least six times during the course of the twentieth century, each time 
to suggest that using connections to cooperate helped people to improve their lives” (p. 14).  
Field states that “Initially, the idea of describing social ties as a form of capital was simply a 
metaphor” (p. 14).  This metaphor “implies that connections can be profitable; like any other 
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form of capital, you can invest in it, and you can expect a decent return on your investment” 
(p. 14). 
 
Over time, Putnam has posited many definitions of social capital (Putnam in Field 2008).  He 
has, for example, described it as “features of social organization, such as trust, norms, and 
networks that can improve the efficiency of society by facilitating coordinated actions” 
(Putnam 1993a as cited in Field 2008). Other definitions include “features of social life –
networks, norms and trust—that enable participants to act more effectively to pursue shared 
objectives” and “features of social organisation…that can improve the efficiency of society by 
facilitating coordinated actions” (p. 35; p. 34).  Putnam also described two types of social 
capital, bridging and bonding.  Bridging social capital is “inclusive” and “tends to bring 
together people across diverse social divisions” while bonding social capital is “exclusive” 
and “tends to reinforce identities and maintain homogeneity” (p. 36).  Bridging social capital 
is more useful for “’linkage to external assets and for information diffusion’” (p. 36).  
“Shared membership of secondary associations” may serve to “bring together individuals 
from quite distinctive and separate small groups” (p. 36).   
 
In his book Bowling Alone, Putnam (2000) discusses the concept of social capital in great 
detail.  While physical capital and human capital relate to “tools and training,” such as “a 
screwdriver…or a college education,” “that enhance individual productivity,” social capital 
includes “social networks and the associated norms of reciprocity” and encompasses a variety 
of structures within society (p. 21).  According to Putnam, this includes one’s extended 
family, civic organizations, “the Internet chat group in which you participate,” and one’s 
“network of professional acquaintances” (p. 21).  Putnam notes that the external effects of 
social capital are not necessarily positive.  As previously noted, bridging is inclusive while 
bonding is exclusive.  Putnam presents the US Civil Rights Movement as an example of 
bridging social capital while an ethnic fraternal organization would be an example of bonding 
social capital.  
 
Some authors have discussed the effects of horizontal and vertical ties (Field 2008, p. 65-66).  
Horizontal ties are “those which create bonds between individuals in the same community or 
social group” while vertical ties are “between different groups up and down the social ladder” 
(p. 66).  There is some evidence that vertical ties have a more pronounced effect on health 
than horizontal ties, which may have “few if any beneficial effects on health” (p. 66).  
44 
Woolcock (Woolcock 2001 in Field 2008) has proposed “linking” as a type of vertical social 
capital; this “consists of relationships up and down the social and economic scale” and 
“allows people to leverage resources, ideas and information from contacts outside their own 
social milieu” (p. 73).  According to Field (2008), linking social capital may have special 
relevance for “community development policies” (p. 73). 
 
Many studies have researched the relationships between social capital and various outcomes, 
such as criminal activity, achievement in educational settings, and health.  In his work, 
Coleman concluded that social capital “could be an asset for disadvantaged social groups” 
(Field 2008, p. 32).  Research has also shown a relationship between social networks and 
mortality rates; there were lower mortality rates among those with stronger social networks 
(p. 63).  Studies of US data suggest that increased social capital “can enable better access to 
health care” (p. 64).  Putnam has suggested four possible explanations for the relationship 
between social capital and health outcomes.  Social networks provide “tangible material 
assistance, which in turn reduces stress” (Field 2008, p. 64). Also, social networks may 
“reinforce healthy norms” (p. 64).  A third possible reason is that “the well-networked citizen 
may lobby more effectively for medical services” (p. 65).  The fourth explanation suggested 
by Putnam is that social “interaction may actually help stimulate the body’s immune system” 
(p. 65-66). 
 
Studies have also researched the effects of social capital on well-being.  According to 
Bornstein (Bornstein et al. 2003 in Field 2008), well-being is a “rather broad notion which 
includes mental health but also encompasses other positive aspects of human development 
such as life satisfaction” (p. 66).  It should be noted that some researchers have questioned the 
legitimacy of generalizing individual level outcomes to “cover a whole population” (p. 67).  
Finding that social capital affects health and well-being on an individual level may not 
translate or extrapolate into the same findings on the population level.  Overall, however, the 
“general pattern of the evidence at present does suggest a broadly positive relationship 
between social capital and health” (p. 67). 
 
Durlauf and Fafchamps (2004) provides a comprehensive overview of social capital studies 
while Kawachi, Subramanian, & Kim (2008) provide an excellent overview of studies and the 
existing literature in regard to social capital and health. As previously mentioned, health 
inequalities and their causes have been examined from a variety of perspectives (Elstad 
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2000).  Programs have targeted certain societal groups, such as women with lower income or 
immigrants, in attempts to increase screening rates.  Less research appears to have focused on 
the outcomes of a breast cancer diagnosis and factors that influence treatment, rehabilitation, 
and recovery.  In addition to emotional and physical issues that must be addressed by breast 
cancer survivors and their families, the economic loss may present an additional burden to 
patients and their families.  There are many factors that may mitigate the potential negative 
effects of cancer diagnosis and treatment.  Socioeconomic status, level of education, and 
access to appropriate treatment facilities have been identified as important factors.  Though 
some research has used concepts of social capital to educate the community by making use of 
“lay health” advisors and existing community structures, such as churches and community 
organizations, the concept of social capital, however, has not been fully explored in relation 
to its effect on rehabilitation and the recovery process.     
 
Studying individual characteristics may not be adequate to explain health outcomes and 
health behaviors.  Studying “neighborhood context” may lead to a more informed analysis 
(Dailey et al. 2007).  The literature indicates that social capital is an important factor in the 
utilization of healthcare services (Kronenfeld 2003).  It also suggests that social capital and 
social participation impact a person’s perception of whether or not she can influence her own 
health (Lindström 2006).  A study by Kothari and Birch (2004) concludes that participation in 
social activities may mitigate the utilization effects on mammography screening of living in 
regions with “less educated” backgrounds.  However, the literature also warns against using 
social capital as the only factor for predicting health service utilization rates (Kronenfeld 
2003; Rosenberg et al. 2005).  Though some articles mention a growth of social capital in the 
form of internet-based breast cancer support groups, many others document the loss of 
community connectedness and support. 
 
The concept of social capital has been studied in regard to its impact on screening 
participation and on health outcomes.  Some studies have suggested that social capital may 
ameliorate some of the effects of the “detrimental contributions of well-established 
biomedical risks” (Putnam 2000, p. 327).  It is possible that social capital may have an effect 
on our health and on health consequences.  This may function in many ways.  For example, 
Putnam describes “tangible assistance,” which might include money or transportation, as well 
as the function of social capital as a “physiological triggering mechanism” (p. 327).  It is also 
possible that communities with high social capital “are best able to organize politically to 
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ensure first-rate medical services” (p. 327).  Putnam mentions that studies have noted “the 
strong correlation between connectedness and health at the community level” (p. 327).  Islam 
et al. (2006) found “a positive association (fixed effect)…between social capital and better 
health” while Folland (2006) predicts a change in risky behavior due to changes in social 
capital status, such as marrying or becoming a parent. 
 
Lindstrom (2000) notes that “social participation is one important aspect of social capital as 
defined by Coleman and Putnam.  This literature stresses the importance of inter-personal 
relations and trust, and social capital is thus partly a contextual trait….In conclusion, social 
participation is the psychosocial factor that is related to a number of health-related behaviors 
and to socioeconomic differences in these behaviors” (Lindstrom 2000). Lindstrom finds that 
“The higher the level of social participation in a neighborhood, the stronger the association 
between living alone, sick leave and unemployment, respectively, and low individual social 
participation” (Lindstrom 2000, p. 46).  According to Lindstrom (2000), Berkman also found 
a relationship between social networks and health; “Social network and support factors may 
affect the health of a person by at least three different pathways” (Berkman et al. 1979 as 
cited in Lindstrom 2000, p. 48). 
 
“More recently a range of authors have suggested that social capital might also be associated 
with positive health outcomes, and argued that Putnam’s ideas might usefully be imported 
into the field of health promotion.  If support could be found for this hypothesis, the 
implication would be that health promoters should put less energy into health education and 
the provision of information about health risks, and more energy into developing programmes 
and policies that enhance levels of social capital in low-health communities” (Campbell in 
Baron, Field, & Schuller 2002, p. 183).  Studies examining the effects of social capital on 
health status have reached different conclusions; this may be due to differences in populations 
studied, research methods used, and how social capital is measured (Van Hooijdonk et al. 
2008).  Some studies have concluded that social capital does not have a "significant" effect on 
population health; Kennelly, O'Shea, and Garvey (2003), for example, found that "per capita 
income and the proportion of health expenditure financed by the government are both 
significantly and positively associated with better health outcomes" but found 
"little...evidence" that social capital has such an effect.  They did find that social capital was 
related to better health outcomes.  It should be noted that their study measured social capital 
using trust and "membership in voluntary associations" (p. 2367).  Using data from the Oslo 
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Health Study 2000, Van der Wel (2007) found that when other variables, such as income and 
education were considered, social capital "is not associated with health"; he also concludes, 
however, that "place matters for health" (p. 71). 
 
Other studies, however, have found links between social capital and health.  Halpern (2005) 
notes that “Having more friends, going to church and taking part in voluntary 
associations…all have some positive impact on health”; he mentions that evidence for this 
statement is supported by “both cross-sectional and longitudinal research” (p. 87).  A study in 
the Netherlands concluded that mortality from cancer was lower in neighborhoods with high 
social capital (Hoojidonk et al. 2008).  However, as in regard to utilization rates of healthcare 
services, social capital alone may not be sufficient to explain health effects.  Some research 
suggests “strong positive links between social capital and educational attainment, economic 
success, health and freedom from crime”; in these instances, however, social capital may be a 
contributing “factor” that works with other factors to create this effect (Field 2008, p. 69).  
Mohseni and Lindstrom (2007) find that "low trust in the health-care system is associated 
with poor self-rated health" (p. 1373).  This may be related to "'not seeking health care when 
needed'" (p. 1373).  This trust component may be important to consider in relation to social 
capital in that trust is considered by many authors to be an important part of social capital. 
Mohseni and Lindstrom (2007) describe trust in the healthcare system as "an institutional 
aspect of social capital" (p. 1373).  Some studies suggest that "the beneficial properties of 
social capital can be found at the individual level"; Poortinga (2006) has findings indicating 
that social capital may not "uniformly benefit individuals living in the same community or 
society" (p. 292).  However, in a study of Swedish data, Sundquist, Johansson, Yang, and 
Sundquist (2006) found that "individual health is affected by differences between 
neighbourhoods in linking social capital" (p. 954). 
 
Islam et al. (2006) investigated the idea that social capital effects on health may vary in 
different countries.  They reached the "tentative conclusion...that an association between 
social capital and health at the individual level is robust with respect to the degree of 
egalitarianism within a country" and that "Area level or contextual social capital may be less 
salient in egalitarian countries in explaining health differences across places."  Folland (2007) 
has concluded that the hypothesis that social capital has an effect on population health is "on 
the whole...remarkably robust" but that there are situations in which the hypothesis "performs 
only weakly" (p. 2342).  However, he clarifies that "it [social capital] distinguishes a clear 
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effect independent of the economic variables" (p. 2352).  This point is particularly important 
because it addresses the possibility that social capital effects may actually be the result of 
socioeconomic variables.  The conclusion that social capital indeed has its own effect on 
health is quite important.  In this thesis, the effects of social capital are examined in 
conjunction with other variables and factors to determine the resulting effect on screening and 
health outcomes in the population surveyed.   
 
There are many components that may contribute to the development of social capital.  
Coleman and Putnam, for example, felt that trust was an important part of social capital 
(Field 2008, p. 70).  Trust may be a part of not only individual relationships but also of “an 
attribute of institutions and groups”; it may also be “based on reputation which is mediated 
through third parties” (p. 71).  In regard to social capital, it has been suggested that different 
types and “dimensions of trust might represent varied ways of accessing resources” (p.71).  
Others feel it is better to view trust as an outcome of social capital rather than as a component 
of social capital itself (p. 72).  This leads to an important issue.  If social capital does indeed 
affect health outcomes and possibly screening issues, to design, implement, and evaluate 
programs, we must be able to in some way identify or quantify social capital. 
 
Therefore, an important question and issue is how to measure social capital (Durlauf 2002).  
In fact, according to Field (2008), “Policy-makers who embrace the idea of promoting social 
capital are virtually unanimous in agreeing that measurement is the central challenge” (p. 
142).  Field mentions several countries that have attempted to measure social capital on a 
national level; these include Britain, Finland, and Australia (p. 143).  The Policy Research 
Initiative (PRI) in Canada has studied the issue of measurement extensively and has 
“recommended indicators…based on network analysis methods, applied to the study of 
network structures and network dynamics”; important features include “the structural 
properties of networks,” such as their size, “the characteristics of network members,” such as 
“the extent of their diversity,” and “their relational properties,” such as “intensity and spatial 
proximity” (p. 143).  Researchers and organizations, such as the OECD, have noted the 
importance of the cultural and local dimensions to the decision of how to measure social 
trust.  The OECD has further suggested that trust may be used as “’an acceptable proxy [for 
social capital]…in the absence of a wider and more comprehensive set of indicators’” (p. 
144).  Field (2008) mentions results of a study from 1995 to 1996 in which Norway was 
found to be the OCED country “with the highest levels of trust” on the World Values Survey 
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(WVS) (p. 144-145).  He is also quick to point out, however, that the results must be 
considered in light of other issues, such as the fact that the question about trust must be 
translated into other languages and that even locally “definitions of trust can vary” (p. 145).  
However, if, as some have argued, trust is more an outcome than a contributor to social 
capital, using trust as a proxy may be ill-advised (p. 145). 
 
Field mentions that policy-makers are increasingly concerned about the “implications of 
social capital” (Field 2008, p. 146).  Identifying ways of building social capital and measuring 
and “monitor[ing] the outcomes” is, however, a challenge (p. 146).  The Forward Strategy 
Unit (FSU) in Britain suggested that “policy should be directed…with a particular focus on 
creating bridging social capital so as to transcend social, ethnic, religious and other divides” 
(p. 147-148).  Fukuyama and others have described education as “a particularly direct means 
of investing in social capital” (p. 148).  Field mentions a history of European governments 
using cooperation with voluntary organizations “as a way of delivering core services” (p. 
149).  There may be many benefits to considering social capital in the development of 
policies; a primary benefit may be that such policies “help improve the effectiveness of 
government, particularly in complex areas where many different arms of government have a 
potential interest in finding solutions” (p. 149).  Another method to “promote” social capital 
may be “partner-based approaches”; in this method, communities are able to “actively” 
participate in “decision-making and programme implementation” (Field 2008, p. 150).   This 
may serve as “a way of promoting sustainable changes in health, as well as tackling 
inequalities in health” (Davies 2001 in Field 2008, p. 150).   
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6. SOCIAL INEQUALITY 
Though it will not be discussed in great detail within this thesis, it is also possible that 
screening participation in part reflects underlying social inequalities and socioeconomic 
differences in particular areas.  The existence of a socioeconomic health gradient is, after all, 
well-documented (Ettner and Grzywacz 2003; Kravdal 2003; Daniels 2008).  Ethner and 
Grzywacz (2003) note that "Health inequalities manifest as a gradient, rather than as a 
distinction between “'haves'” and “'have nots'” (p. 441).  Worldwide, screening patterns have 
been linked to socioeconomic status, education, and immigrant status.  In Norway, previous 
studies have found that participation in screening is related to trust, gratitude, and 
convenience (Østerlie et al. 2008).  Screening behaviors may be linked to overall health.  
Therefore, it may also be pertinent to discuss the relationship between health and 
socioeconomic status.  Within Norway, Dahl, Elstad, Hofoss, and Mollard (2006) found "the 
emergence of regional-level income inequality effects on mortality"; they note that "these 
effects were particularly marked among socioeconomically disadvantaged groups" (p. 2562).  
Internationally, numerous studies have researched the interactions between socioeconomic 
status and health.  As Edmondson (2003) notes, social capital is "currently being discussed as 
a source of support for health" (p. 1723).  Based on US data, Adams et al. (2003) examined 
links between health and socioeconomic status.  They could not reach firm conclusions but 
did not rule out the possibility that "SES[socioeconomic status]-linked preventative care 
influences onset of chronic and mental diseases" (p. 3).  They also mention previous studies 
"with the general finding that higher socioeconomic status (SES) is associated with better 
health and longer life" (p. 3).  This effect has been documented for a wide variety of variables 
associated with socioeconomic status, including “wealth, education, occupation, income, 
[and] level of social integration” (p. 3). 
 
Bolin, Lindgren, Lindstrom, and Nystedt (2003) investigate the interactions between social 
capital and health.  Using a definition of social capital as "having a close friend outside the 
family," they predicted that "the amount of social capital is positively related to the level of 
health" (p. 2379).  Based on data from Sweden,  they conclude that "social capital is 
positively related to the level of health capital" and that "the level of social capital declines 
with age, is lower for those married or cohabiting, and is lower for men than for women" (p. 
2379).  They also mention previous studies that investigated the potential links between social 
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capital and health.  Some researched has indicated an association between higher social 
capital and lower total mortality (p. 2379). 
 
Though many studies have now recognized that social capital may have an effect on health 
and health outcomes, it is challenging to appropriately conceptualize, measure, and capture 
social capital and social capital effects.  Harpham, Grant, & Thomas (2002), for example, 
discuss issues related to the measurement of social capital in health surveys, such as 
"cognitive, structural, bonding and bridging social capital."  Harpham, Grant, and Thomas 
(2002) credit Bain and Hicks (1998) for the "disaggregat[ion]" of social capital into structural 
and cognitive components (Harpham, Grant, and Thomas 2002, p. 106).  Harpham, Grant, 
and Thomas (2002) describe the two components as follows: "The Structural component 
includes extent and intensity of associational links or activity, and the cognitive component 
covers perceptions of support, reciprocity, sharing and trust.  At the simplest level, these two 
components can be respectively characterized as what people 'do' and what people 'feel' in 
terms of social relations" (p.106).  These concepts add additional dimensions to consider in 
evaluating or discussing social capital. 
 
As Campbell and Gillies (2001) discuss, utilizing social capital and results of social capital 
studies to inform policy decisions and actually positively influence social capital itself 
requires further study.  Baron, Field, and Schuller (2002) discuss the “potential role” of social 
capital in health education and public health (p. 185).  Crothers (in McLean, Schultz, and 
Steger 2002) notes that attempts to “regenerate or reinvigorate social capital must be sensitive 
to the values, goals, and ideals of local populations” (p. 219).  If we conclusively learn that 
social capital does have an effect on health and on screening, finding a way to utilize that 
information to positively influence health outcomes, well-being, and participating in 
screening will be a further challenge. 
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7. DATA 
Data was collected using questionnaires sent to 3000 members of the Foreningen for 
Brystkreftopererte.  By April 28, 2009, 1241 responses had been received.  For various 
reasons, two respondents chose to opt out of completing the survey.  The information and 
statistics that follow are based on the valid responses for the remaining 1239 returned 
surveys.  If a respondent did not enter information for a particular question, such as year of 
birth or use of private screening methods, the statistics given are based on responses from 
those who did enter information for the relevant questions.  Three respondents did not list 
their year of birth and are not included in the figure below.  An overview of the valid 
responses received by April 28, 2009, is given below in Figure 2. 
Figure 2. Questionnaire Responses 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surveys Mailed: 3000 
Completed Surveys Returned: 1239 
Respondents 40 to 49: 
227 (18.4%) 
Respondents 50 to 69: 
1009 (81.6%) 
Screening: 
Yes   91   (40.4%) 
No   134 (59.6%) 
Screening: 
Yes  787  (80.2%) 
No   194  (19.8%) 
Type of 
Screening: 
Public     28 
Private    50 
Both        13 
Type of 
Screening: 
 Public     426 
 Private   155 
 Both       206 
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8. METHOD  
Following the completion of a literature search, a questionnaire was developed in 
collaboration with Dr. Eline Aas, the Foreningen for Brystkreftopererte, and HERO, to elicit 
information about variables that may affect breast cancer screening, treatment, rehabilitation, 
and health outcomes.  These variables included age, county, education, employment status, 
income, usage and frequency of public and private breast cancer screening options, and social 
capital factors, such as family relationships, friendships, and community and organizational 
involvement. Questions were also asked about the use of rehabilitation options and the usage 
of genetic testing. The questionnaire was sent to 3000 women aged 40 to 69 who are 
members of the Norwegian Foreningen for Brystkreftopererte. The response rate was 
approximately 41.4%; 1241 questionnaires were returned.  Of the returned questionnaires, 
1239 had been completed.   
 
Based on the literature review, several variables were identified that may be expected to have 
a positive influence on screening rates.  Those variables are as follows:  age, education, 
personal and household income, participation in the workforce, social capital as measured by 
household composition, number of friends, and participation in organization, and perceived 
risk as evidenced by prior genetic testing or willingness to take a genetic test.  The following 
variables were expected to evidence a negative effect on screening rates:  travel distance to 
public and private screening options and later introduction of public mammography screening 
to particular counties.  The data was analyzed using SPSS 16 to investigate the hypotheses 
about the potential effects on screening and to determine which variables impacted breast 
cancer screening and the choice of screening options.  Descriptive statistics cross tabulation, 
multinomial logistic regression, and ordinary least squares regression were utilized to identify 
the variables that impact screening and the choice of screening options.  Due to sample 
limitations, an appropriate model could not be constructed to describe the probability that a 
woman will participate in screening.  Descriptive statistics and an overview of trends and 
tendencies in the data are, however, provided in Section 9 “Results and Analysis.” 
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9. RESULTS AND ANALYSIS 
 
Data analysis revealed some trends in mammography screening patterns.  The probability of 
having participated in mammography screening appeared to be influenced by county of 
residence, age, education, and travel distance to screening.   
9.1 Descriptive Statistics 
A greater percentage of older women and women with university or college education had 
participated in screening. Women with university or college education also had a higher 
percentage of participation in private screening. Women 55 and older had a higher percentage 
of participation in both public and private screening.  Also, a higher percentage of women 
with personal income of 400 000 NOK or higher (at the time of diagnosis) had participated in 
screening when compared to women with personal income of less than 400 000 NOK.  A 
smaller percentage of residents in the following counties had been screened in comparison to 
the other counties:  Finnmark, Nordland, Nord-Trøndelag, Telemark, Sogn og Fjordane, 
Vestfold, Hordaland, and Møre og Romsdal.  More than one-third of respondents in 
Finnmark, Hordaland, Nordland, Nord-Trøndelag, Vestfold, and Telemark had not been 
screened prior to their breast cancer diagnosis.  The screening percentage was approximately 
66.7% for Sogn og Fjordane.  A higher percentage of respondents had been screened in the 
following counties:  Oslo, Akershus, and Vest-Agder.  Approximately 85.7% of respondents 
from Vest-Agder had been screened prior to diagnosis while approximately 85.4% of Oslo 
County respondents had been screened.  The screening percentages for each county based on 
valid survey data is listed in Table 10. 
 
In regard to work, no real conclusions could be drawn.  Older people were more likely to have 
been screened, but it is also possible that they are more likely to have entered retirement or 
screening ages, which affects the screening results for employed and unemployed 
respondents.  Selected descriptive statistics are provided in Tables 3, 4, and 5.  Women below 
the age of 50 are not generally part of the public mammography screening program.  
Therefore, selected separate descriptive statistics for the 40 to 49 age group and for the 50 and 
above age group are provided in Tables 6 through 9.  A higher percentage of women in the 40 
to 49 age group had taken a genetic test for breast cancer.  However, there were fewer 
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respondents from the 40 to 49 age group.  Within the 50 to 69 age group, women with an 
annual household income of 400 000 NOK were more likely to participate in private 
screening than women with household incomes of less than 400 000 NOK. 
Table 3.  Screening Status  (N=1239) 
Variable Screening Status 
Yes No 
Average Standard 
Deviation 
Average Standard 
Deviation 
Age 57.64 6.61 54.62 6.82 
Travel Time (Public) (min) 37.57 37.42 39.71 37.62 
Travel Time (Private) (min) 45.87 51.98 44.64 52.82 
Household Income (NOK) 
 (At Diagnosis)  
743324 2.67 x 106 643663 6.48 x 105 
 
Table 4.  Variables Based on the Type of Screening Used By Those Screened (N=1239) 
Variable Type of Screening 
Public Only Private Only Both Public and 
Private 
Average Standard 
Deviation 
Average Standard 
Deviation 
Averag
e 
Standard 
Deviation 
Age 58.72 5.97 54.24 6.72 59.18 5.73 
Travel Time (Public) (min) 36.98   37.91 36.38 34.95 35.43 32.25 
Travel Time (Private) 52.82 63.74 40.35 37.86 45.75 55.03 
Household Income (NOK) 
(At Diagnosis) 
625446 2.85 x 105 675041 2.88 x 105 719995 1.02 x 10 
6 
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Table 5.  Socioeconomic Variables Based on Screening Status (Percentages are not 100% 
for some variables due to missing or invalid responses for some questions) (N=1239) 
Variable Category Screening  Status 
Yes No 
Age Under 50 years old 40.1 59.0 
50 to 69 years old 78.0 19.2 
Living Status  
(At Time of 
Diagnosis) 
Alone 77.4 21.5 
With spouse or cohabitant 71.0 26.1 
Without spouse or cohabitant 60.9 39.1 
With someone aged 18 or older 67.9 30.1 
With someone under age 18 48.7 49.0 
Income (Household) 
(At Time of 
Diagnosis) 
Under 100,000 NOK 60.8 37.3 
100,000 – 199,999 NOK 67.8 30.3 
200,000 – 399,999 NOK 72.6 24.8 
400,000 – 599,999 NOK 74.0 24.9 
600,000 – 999,999 NOK 70.0 30.0 
1 million NOK or more 50.0 50.0 
Education Primary School 77.8 18.1 
High School 69.5 28.5 
University/College  68.8 29.6 
Employment status 
 (At time of 
diagnosis) 
Employed (Yes) 69.8 27.6 
Not Employed (No) 77.1 21.5 
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Table 6. Variables Based on the Type of Screening Used by 40 to 49 Age Group (N= 227 
total respondents aged 40 to 49)* 
 
Variable Category Type of Screening 
Public Only Private Only Both Public and 
Private 
Percent Valid 
Responses 
Percent Valid 
Responses 
Percent Valid 
Responses 
Education Primary School 7.1 28 6.1 49 7.7 13 
High School 46.4 38.8 23.1 
University/College  46.4 55.1 69.2 
Employment Yes 78.6 28 90.0 50 92.3 13 
No 21.4 10.0 7.7 
Number of Good 
Friendships 
None 0 27 2.0 50 0 13 
1-3 11.1 10.0 7.7 
4-6 29.6 20.0 30.8 
7-9 3.7 14.0 23.1 
10 or more 55.6 54.0 38.5 
Genetic Testing 
for Breast 
Cancer 
Yes 37.0 27 38.8 49 30.8 13 
No 37.0 22.4 38.5 
No Offer 25.9 38.8 30.8 
Genetic Testing 
for Breast 
Cancer if 
Offered 
Yes 85.7 28 71.4 49 84.6 13 
No 0.0 2.0 7.7 
Do not know 14.3  26.5  7.7  
Living Status 
(Spouse or 
Cohabitant) 
With Spouse or 87.5 24 87.8 49 84.6 13 
Without Spouse or 
Cohabitant 
12.5 12.2 23.1 
Living Status 
(Persons Over 
Age 18) 
Yes 20.0 20 28.6 42 25.0 12 
No 80.0 71.4 75.0 
Living Status 
(Persons Under 
Age 18) 
Yes 75.0 24 83.0 47 83.3 12 
No 25.0 17.0 16.7 
Personal Income 
(NOK) 
(At Diagnosis) 
Under 100,000 NOK 3.6 28 2.0 50 0 13 
100,000 – 199,999 14.3 12.0 7.7 
200,000 – 399,999 50.0 58.0 53.8 
400,000 – 599,999 28.6 24.0 30.8 
600,000 – 999,999 3.6 4.0 7.7 
1 million NOK or more 0 0 0 
Household 
Income (NOK) 
(At Diagnosis) 
Under 100,000 NOK 4.2 24 0 46 0 10 
100,000 – 199,999 4.2 0 0 
200,000 – 399,999 20.8 8.7 20.0 
400,000 – 599,999 12.5 23.9 10.0 
600,000 – 999,999 41.7 37.0 40.0 
1 million NOK or more 16.7 30.4 30.0 
*Percentages are based on the entire group of respondents aged 40 to 49.  Also, some respondents did 
not respond to every question.  Therefore, in this and other tables, the percentages do not equal 100% 
in all cases. 
Table 7. Variables Based on the Type of Screening Used by 50 to 69 Age Group (N=1009) 
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Variable Category Type of Screening 
Public Only Private Only Both Public and Private 
Percent Valid* Percent Valid Percent Valid 
Education Primary School 32.5 525 16.8 155 25.9 205 
High School 27.1 34.8 29.8 
University/College  39.5 48.4 42.9 
Employment Yes 76.4 423 88.4 155 79.6 206 
No 23.6 11.6 20.4 
Number of Good 
Friendships 
None 0.7 413 0 149 1.5 199 
1-3 11.9 12.1 11.6 
4-6 28.6 37.6 29.1 
7-9 13.8 11.4 11.6 
10 or more 45.0 38.9 46.2 
Genetic Testing for 
Breast Cancer 
Yes 15.7 389 21.6 148 14.4 187 
No 52.2 50.7 46.5 
No Offer 32.1 27.7 39.0 
Genetic Testing for 
Breast Cancer if 
Offered 
Yes 64.8 415 72.2 151 69.0 203 
No 14.5 9.3 8.4 
Do not know 20.7 18.5 22.7 
Living Status 
(Spouse or 
Cohabitant) 
With Spouse or 
Cohabitant 
81.9 414 86.7 150 76.4 199 
Without Spouse or 
Cohabitant 
18.1 13.3 23.6 
Living Status 
(Persons Over Age 
18) 
Yes 15.5 342 30.1 123 18.3 175 
No 84.5 69.9 81.7 
Living Status 
(Persons Under Age 
18) 
Yes 14.4 341 27.1 129 11.8 170 
No 85.6 72.9 88.2 
Personal Income 
(NOK) 
(At Diagnosis) 
Under 100,000 NOK 3.9 412 4.0 151 3.4 204 
100,000 – 199,999 18.0 9.9 17.6 
200,000 – 399,999 62.9 63.6 63.2 
400,000 – 599,999 13.6 19.2 12.3 
600,000 – 999,999 1.5 2.6 3.4 
1 million NOK or 
more 
0.2 0.7 0 
Household Income 
(NOK) 
(At Diagnosis) 
Under 100,000 NOK 2.0 347 3.1 127 1.8 168 
 
100,000 – 199,999 2.6 0.8 2.4 
200,000 – 399,999 20.5 9.4 21.4 
400,000 – 599,999 24.5 27.6 20.2 
600,000 – 999,999 40.6 47.2 40.5 
1 million NOK or 
more 
9.8 11.8 13.7 
*Number of Valid Responses 
 
Table 8. Total Number of Screenings for the 40 to 49 Age Group (N= 227) 
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Variable Category Total Number of Screenings 
1 to 3 4 to 6 7 to 9 10 or more 
Percent Valid Percent Vali Percent Valid Percent Valid 
Education Primary School 9.1 5 7.4 2 7.1 1 0 0 
High School 45.5 25 37 10 28.6 4 27.3 3 
University/College  45.5 25 55.6 15 64.3 9 72.7 8 
Employment Yes 85.7 48 96.3 26 85.7 12 100 11 
No 14.3 8 3.7 1 14.3 2 0 0 
Number of 
Good 
Friendships 
None 1.8 1 0 0 0 0 0 0 
1-3 14.5 8 3.7 1 7.1 1 0 0 
4-6 23.6 13 37.0 10 35.7 5 27.3 3 
7-9 7.3 4 22.2 6 7.1 1 9.1 1 
10 or more 52.7 29 37.0 10 50.0 7 63.6 7 
Genetic Testing 
for Breast 
Cancer 
Yes 33.9 19 34.6 9 35.7 5 36.4 4 
No 30.4 17 26.9 7 42.9 6 36.4 4 
No offer 35.7 20 38.5 10 21.4 3 27.3 3 
Genetic Testing 
for Breast 
Cancer if 
Offered 
Yes 70.9 39 92.3 24 85.7 12 63.6 7 
No 1.8 1 0 0 0 0 9.1 1 
Do Not Know 27.3 15 7.7 2 14.3 2 27.3 3 
Living Status 
(Spouse or 
Cohabitant) 
With Spouse or 
Cohabitant 
84.6 44 85.2 23 92.3 100 100 10 
Without Spouse or 
Cohabitant 
15.4 8 14.8 4 7.7 0 0 0 
Living Status 
(Persons Over 
Age 18) 
Yes 26.7 12 25 6 10 33.3 33.3 3 
No 73.3 33 75 18 90 66.7 66.7 6 
Living Status 
(Persons Under 
Age 18) 
Yes 75.9 41 76 19 91.7 100 100 10 
No 24.1 13 24 6 8.3 0 0 0 
Personal 
Income (NOK) 
(At Diagnosis) 
Under 100,000 1.8 1 3.7 1 0 0 0 0 
100,000 – 199,999 12.5 7 14.8 4 14.3 18.2 18.2 2 
200,000 – 399,999 55.4 31 74.1 20 57.1 36.4 36.4 4 
400,000 – 599,999 26.8 15 7.4 2 21.4 36.4 36.4 4 
600,000 – 999,999 3.6 2 0 0 7.1 9.1 9.1 1 
1 million NOK or 
more 
0 0 0 0 0 0 0 0 
Household 
Income (NOK) 
(At Diagnosis) 
Under 100,000 2.0 1 0 0 0 0 10 1 
100,000 – 199,999 2.0 1 0 0 0 0 0 0 
200,000 – 399,999 1.8 6 23.8 5 18.2 2 0 0 
400,000 – 599,999 17.6 9 9.5 2 18.2 2 10 1 
600,000 – 999,999 41.2 21 61.9 13 45.5 5 30 3 
1 million NOK or 
more 
25.5 13 4.8 1 18.2 2 50 5 
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Table 9. Total Number of Screenings for the 50 to 69 Age Group (N=1009) 
Variable Category Total Number of Screenings 
1 to 3 4 to 6 7 to 9 10 or more 
Percent Valid Percent Valid Percent Valid Percent Valid 
Education Primary School 22.2 49 26.3 60 32.8 45 34.8 62 
High School 28.5 63 31.6 72 29.2 40 27.5 49 
University/College  49.3 109 42.1 96 17.8 50 37.6 67 
Employment Yes 85.9 189 79.1 18.2 79.9 111 79.8 142 
No 14.1 31 20.9 48 20.1 28 20.2 36 
Number of 
Good 
Friendships 
None 0.9 2 1.3 3 0 0 0.6 1 
1-3 12.5 27 13.1 30 10.4 14 11.1 19 
4-6 30.6 66 31.9 73 30.6 41 29.2 50 
7-9 13.0 28 11.8 27 17.9 24 9.4 16 
10 or more 43.1 93 41.9 96 41.0 55 49.7 85 
Genetic Testing 
for Breast 
Cancer 
Yes 15.8 32 14.7 31 21.7 28 19.9 32 
No 48.8 99 51.7 109 47.3 61 49.1 79 
No Offer 35.5 72 33.6 71 31.0 40 31.1 50 
Genetic Testing 
for Breast 
Cancer if 
Offered 
Yes 66.7 146 67.8 154 66.9 91 71.1 123 
No 10.5 23 10.6 24 11.0 15 15.0 26 
Do not know 22.8 50 21.6 49 22.1 30 13.9 24 
Living Status 
(Spouse or 
Cohabitant) 
With Spouse or 
Cohabitant 
80.6 174 78.4 174 86.9 119 87.9 153 
Without Spouse or 
Cohabitant 
19.4 42 21.6 48 13.1 18 12.1 21 
Living Status 
(Persons Over 
Age 18) 
Yes 27.0 48 17.7 34 16.1 18 17.8 26 
No 73 130 82.3 158 83.9 94 82.2 120 
Living Status 
(Persons Under 
Age 18) 
Yes 25.8 47 12.8 24 17 19 17 25 
No 74.2 135 87.2 163 83 93 83 122 
Personal 
Income (NOK) 
(At Diagnosis) 
Under 100,000 2.3 5 4.4 10 3.6 5 4.7 8 
100,000 – 199,999 13.2 29 15.9 36 18.1 25 18.6 32 
200,000 – 399,999 67.1 147 63.3 143 67.4 93 59.3 102 
400,000 – 599,999 14.2 31 14.2 43 9.4 13 14.5 25 
600,000 – 999,999 2.7 6 2.2 5 1.4 2 2.9 5 
1 million NOK or 
more 
0.5 1 0 0 0 0 0  
Household 
Income (NOK) 
(At Diagnosis) 
Under 100,000 1 2 2.1 4 1.7 2 2.9 4 
100,000 – 199,999 2.1 4 3.7 7 2.6 3 0 0 
200,000 – 399,999 15.2 29 19.4 37 12.9 15 17.3 24 
400,000 – 599,999 24.1 46 24.6 47 29.3 34 25.2 35 
600,000 – 999,999 48.7 93 41.4 79 42.2 49 41.7 58 
1 million NOK or 
more 
8.9 17 8.9 17 11.2 13 12.8 18 
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Table 10.  Screening Percentage By County (N= 1193 valid responses) 
County Year Screening 
Was Introduced 
Screening (%) Valid Responses 
Akershus  1996 81.2 154 
Aust-Agder  1999 75.0 12 
Buskerud  2001 71.1 83 
Finnmark  2000 40.0 15 
Hedmark  2003 73.8 61 
Hordaland  1996 65.9 85 
Møre og Romsdal  2002 67.1 76 
Nordland  2001 60.5 81 
Nord-Trøndelag  2001 63.3 30 
Oppland  2002 73.0 37 
Oslo  1996 85.4 137 
Rogaland  1995 75.3 77 
Sogn og Fjordane  2003 66.7 18 
Sør-Trøndelag  2001 73.8 61 
Telemark  1999 65.4 26 
Troms  2000 70.0 60 
Vestfold  2004 66.2 80 
Vest-Agder 1999 85.7 28 
Østfold  2001 73.6 72 
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9.2 Limitations 
As mentioned previously, there are numerous limitations to this study.  The survey was 
distributed to women who have been diagnosed with breast cancer.  This provides a far 
different sample than if it were randomly distributed to women in the general population of 
Norway.  Also, the response rate by April 28 point was less than 50%.  An additional 
difficulty is the possibility of selection bias in regard to age.  Most of the responses were 
received from women aged 50 and older, which may further serve to skew the results of this 
analysis.  Another consideration is survey design.  Information about travel distance to public 
and private screening options was not obtained for all respondents or for most of the 
respondents who had not been screened prior to diagnosis.  Therefore, it is possible that more 
information could have been gained about travel distance as a barrier to screening. It is also 
possible for respondents within the same county to have different travel distances to screening 
options or to make use of screening options in other counties.  
 
Also, the way in which respondents understood the term “offentlig” mammography screening 
may have varied.  Some respondents specified the frequency of “kontroll” healthcare visits in 
contrast with actually mammography visits, so it is possible that some respondents included 
“kontroll” visits in their total number of mammography screenings.  Many respondents did 
not recall the year of their first mammography screening visit or the total number of times 
they had been screened.  Also, some respondents included the screening visit in which they 
received their breast cancer diagnosis while others did not.  Another complicating issue is that 
many respondents were not sure when they were first screened or of how many times they had 
been screened.  When this information was not provided or an estimate was not given, it was 
difficult to include the respondents in the overall analysis of the use of screening options.  
The response set was smaller for some variables, and therefore creating an accurate model 
was problematic. 
9.3 AVENUES FOR FURTHER ANALYSIS 
Future analyses of a more complete data set of questionnaires could include a multinomial 
logistic regression to identify potentially significant variables in breast cancer screening.  
Various multinomial logistic regressions were performed in the analyses of the current data 
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set.  However, as mentioned in the “Limitations” Section, there were limitations related to 
numerous missing variables, the small sample size and response set for some questions, and 
also possible selection bias problems in the current data set.  Due to those limitations, 
presenting results and a model for predicting the probability of a woman attending public, 
private, or both types of breast cancer screening would be a bit premature and are not 
included in the Results section.  However, if more surveys are received and with a more 
complete data set that is more representative and has a more complete response set, the results 
of such an analysis could prove quite useful. 
 
With such a data set, an ordinary least squares regression comparing the total number of 
screenings in the 40 to 49 age group to the total number of screenings in the 50 to 69 age 
group could also be performed to assist in determining if there are any significant differences 
in screening among those who have access to public mammography screening and those who 
do not.  Preliminary regression results suggest that there are significant differences.  
However, as previously mentioned, more data and responses are needed prior to presenting a 
valid result.  Comparisons between these two age groups are of particular interest in Norway.  
While woman aged 50 and above are called in to public mammography screening in Norway, 
women below the age of 50 are not generally a part of routine public mammography 
screening.  Descriptive statistics are provided for both age groups in the “Descriptive 
Statistics” section.  However, the responses were predominately from the 50 and above age 
group.  If a broader range of responses are received from the 50 and below age group or if a 
survey was performed that gathered more responses from the general population, analyses 
could be performed using the more complete and representative sample set. 
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10. CONCLUSIONS 
As McGuire, Henderson, and Mooney (2005) state, "Screening for breast cancer may increase 
women's life-expectancy through detection and treatment of disease" (p. 84).  It may also 
have positive effects on a woman's quality of life if it detects cancer in the earlier stages, 
thereby enabling more conservative treatment. Identifying variables that influence screening 
participation rates can assist in the development of policies and programs to target 
populations who are less likely to be screened.   It is possible that learning more about social 
capital and other variables that influence the likelihood of a woman being screened for breast 
cancer may assist in developing programs or information that address potential barriers to 
screening.  If we had learned, for example, that social capital does indeed affect a person’s 
likelihood of participating in breast cancer screening in Norway, this may provide us with 
information on how to better present information about screening to segments of the 
population.  It may also be possible that there are access issues that may need to be addressed.  
Identifying the relevant variables that influence screening participation can add useful 
information for the further development of the Norwegian Breast Cancer Screening Program. 
 
In this paper, the effects of both formal and informal social capital were explored in 
conjunction with other more widely researched factors, such as socioeconomic status, on 
screening issues in the breast cancer screening population.  More formal social capital, for 
example, may include participation in existing community organizations and social activities 
while informal social capital may consist of family relationships and friendships.  In addition 
to examining the possible effects of social capital on screening, this thesis has also discussed 
the potential effects of social capital on health outcomes.  Another topic involves utilization 
rates in Norway of public and private (opportunistic) screening options and the effects of 
these screening options.  Access to relevant resources and the extent to which access is 
influenced by social capital as well as the issue of whether this leads to social inequality in 
screening and detection rates are also important issues.  The analysis from the results of the 
questionnaire helps in the identification of important variables affecting screening rates.  It 
also provides information on the effects of social capital and social inequalities on health 
outcomes.  
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The expectation was that higher social capital would be reflected in higher screening rates and 
perhaps also in the use of a wider variety of screening options.  The effect, if any, of social 
capital on health outcomes was expected to be positive.  Based on the current results, it can 
not be stated that social capital has evidenced a statistically significant or demonstrable effect 
on breast cancer screening or on the health outcomes of screening. The results have, however, 
identified other variables that influence participation in screening.  This information may be 
useful in the development of policies and programs to increase screening uptake.  Other 
sections of the survey may also prove useful for the development of programs to support 
women and improve their health outcomes following diagnosis.  The questionnaire also tried 
to identify areas in which economic loss due to illness is not adequately mitigated, and the 
results from this should also prove quite useful in developing follow-up and support services 
for women during and after breast cancer treatment.  It is not only important to increase 
screening rates.  Providing adequate programming, support, and information to women during 
the treatment and rehabilitation stages is also vitally important. 
 
Based on the analysis of the questionnaires, age, county, personal and household income, and 
travel distance to screening may have an effect on screening usage.  Distance to types of 
screening options has also demonstrated an effect on which type of screening is used in 
particular counties.  Also, as expected, income may also influence the use of private screening 
outcomes.  Based on these results, it may be useful to increase the usage of the 
“Mammography Bus” and other options to increase screening in counties with longer travel 
distances to screening.  Mammography screening has been evidenced to decrease mortality 
rates from breast cancer and to detect breast cancer in earlier stages of disease.  Future studies 
may benefit from the refinement of the questionnaire used for this study and from the 
additional information gained about variables impor
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